Human LIG-1 homolog (HLIG-1)

Abstract

HLIG-1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HLIG-1 polypeptides and polynucleotides in the design of protocols for the treatment of neurological disorders such as Alzheimer's disease, multiple sclerosis and abnormal neural development; endocrine disorders such as diabetes; and heart disease, among others and diagnostic assays for such conditions.

Description

FIELD OF INVENTION

This invention relates to newly identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to the immunoglobulin superfamily, hereinafter referred to as HLIG-1. The invention also relates to inhibiting or activating the action of such polynucleotides and polypeptides.

BACKGROUND OF THE INVENTION

The immunoglobulin (Ig) gene superfamily comprises a large number of cell surface glycoproteins that share sequence homology with the V and C domains of antibody heavy and light chains. The Ig superfamily molecules function as receptors for antigen, receptors or counter-receptors for other cell surface molecules including other Ig superfamily molecules and adhesion molecules, and as receptors for cytokines (A. F. Williams et al., Annu. Rev. Immunol. 6:381-405, 1988).

Another protein fold motif of this family is the leucine rich repeat (LRR), which is a segment of 20-29 amino acids with a signature pattern of 4 consensus leucines and an asparagine. LRRs most commonly occur in multiple tandem arrays and have been identified in more than 60 different proteins of diverse function (reviewed in B. Kobe and J. Deisenhofer, Trends-Biochem-Sci. 19, 415-21 (1994) and in B. Kobe and J. Deisenhofer, Curr Op in Struct Biol 5, 409-416 (1995)). Examples of this family are found in a range of organisms and include the insulin binding protein acid labile subunit (ALS), the morphogenic protein "18 wheeler," the neural development protein slit, the receptors for chorionic gonadotropin, lutrophin, and follitrophin, and the transcriptional regulator, CIITA. The crystal structure of one member of this family, porcine ribonuclease inhibitor (RI), has been determined (B. Kobe and J. Deisenhofer, Nature 366, 751-756 (1993)) and serves as a model for the folding of the LRR regions in other proteins. RI consists entirely of 15 LRRs which assume a .beta.-strand-turn-helix-turn conformation and assemble into a toroid shaped horseshoe structure. Although diverse in function and cellular localization, a common property of members of the LRR family is protein interaction which in several instances has been mapped to the unusual structural region of the LRRs. One indication of the nature of this interaction is revealed by the structure of the complex between RI-and its non-native ligand ribonuclease A (B. Kobe and J. Deisenhofer, Nature 374, 183-186 (1995)). As revealed in both the complexed and uncomplexed structure, the conserved residues of the LRR repeat are buried, serving as foundations for the fold. The specificity for differential protein recognition lies in other non-conserved residues in the repeat. A second sequence motif often associated with LRRs is a cysteine cluster containing 4 similarly spaced cysteines and a proline residue. These clusters lie immediately N- or C-terminal, or both, to the tandem LRRs, and most frequently occur in proteins associated with adhesion or receptor function. One example of this subfamily is the insulin binding protein acid labile subunit (ALS) (S R Leong et al., Mol Endrocrinol 6, 870-876 (1992)), which forms dimeric complexes with insulin binding proteins (IBP) and trimeric complexes with IBPs and insulin like growth factors (IGFs). These complexes restrict IGFs to the vascular compartment with a long extension of their circulating 1/2 life, and thereby are critical in the development of endocrine function and in the regulation of glucose homeostasis. A second example is the drosophila protein slit, a secreted protein of glial cells, which is involved in the development of axonal pathways (J M Rothberg et al., Genes Develop. 4, 2169-2187 (1990).

Recently, LIG-1, a novel mouse membrane glycoprotein, which contains 15 leucine-rich repeats (LRR) and flanking cysteine clusters and 3 Ig-like domains of the C2-type, was identified by Y. Suzuki et al., J. Biol. Chem. 271:22522-22527, (1996). LIG-1 is expressed predominantly in the mouse brain, restricted to a small subset of glial cells such as the Bergmann glial cells and those in the nerve fiber layer of the olfactory bulb. Based on its unique molecular structure and tissue-specific expression, LIG-1 may play a role in neuroglial differentiation, development, and/or maintenance of neural function. This indicates that these receptors have an established, proven history as therapeutic targets. Clearly there is a need for identification and characterization of further receptors which can play a role in preventing, ameliorating or correcting dysfunctions or diseases, including, but not limited to, neurological disorders such as Alzheimer's disease, multiple sclerosis and abnormal neural development; endocrine disorders such as diabetes; and heart disease.

SUMMARY OF THE INVENTION

In one aspect, the invention relates to HLIG-1 polypeptides and recombinant materials and methods for their production. Another aspect of the invention relates to methods for using such HLIG-1 polypeptides and polynucleotides. Such uses include the treatment of neurological disorders such as Alzheimer's disease, multiple sclerosis and abnormal neural development; endocrine disorders such as diabetes; and heart disease, among others. In still another aspect, the invention relates to methods to identify agonists and antagonists using the materials provided by the invention, and treating conditions associated with HLIG-1 imbalance with the identified compounds. Yet another aspect of the invention relates to diagnostic assays for detecting diseases associated with inappropriate HLIG-1 activity or levels.

DESCRIPTION OF THE INVENTION

Definitions

The following definitions are provided to facilitate understanding of certain terms used frequently herein.

"HLIG-1" refers, among others, to a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2, or an allelic variant thereof.

"Receptor Activity" or "Biological Activity of the Receptor" refers to the metabolic or physiologic function of said HLIG-1 including similar activities or improved activities or these activities with decreased undesirable side-effects. Also included are antigenic and immunogenic activities of said HLIG-1.

"HLIG-1 gene" refers to a polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO:1 or allelic variants thereof and/or their complements.

"Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.

"Isolated" means altered "by the hand of man" from the natural state. If an "isolated" composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.

"Polynucleotide" generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications has been made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

"Polypeptide" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. See, for instance, PROTEINS--STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993 and Wold, F., Posttranslational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter et al., "Analysis for protein modifications and nonprotein cofactors", Meth Enzymol (1990) 182:626-646 and Rattan et al., "Protein Synthesis: Posttranslational Modifications and Aging", Ann NY Acad Sci (1992) 663:48-62.

"Variant" as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

"Identity" is a measure of the identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. "Identity" per se has an art-recognized meaning and can be calculated using published techniques. See, e.g.: (COMPUTATIONAL MOLECULAR BIOLOGY, Lesk, A. M., ed., Oxford University Press, New York, 1988; BIOCOMPUTING: INFORMATICS AND GENOME PROJECTS, Smith, D. W., ed., Academic Press, New York, 1993; COMPUTER ANALYSIS OF SEQUENCE DATA, PART I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; SEQUENCE ANALYSIS IN MOLECULAR BIOLOGY, von Heinje, G., Academic Press, 1987; and SEQUENCE ANALYSIS PRIMER, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there exist a number of methods to measure identity between two polynucleotide or polypeptide sequences, the term "identity" is well known to skilled artisans (Carillo, H., and Lipton, D., SIAM J Applied Math (1988) 48:1073). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H., and Lipton, D., SIAM J Applied Math (1988) 48:1073. Methods to determine identity and similarity are codified in computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCS program package (Devereux, J., et al., Nucleic Acids Research (1984) 12(1):387), BLASTP, BLASTN, FASTA (Atschul, S. F. et al., J Molec Biol (1990) 215:403).

As an illustration, by a polynucleotide having a nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO:1 is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO:1. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5 or 3 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.

Similarly, by a polypeptide having an amino acid sequence having at least, for example, 95% "identity" to a reference amino acid sequence of SEQ ID NO:2 is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of SEQ ID NO: 2. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

Polypeptides of the Invention

In one aspect, the present invention relates to HLIG-1 polypeptides (or HLIG-1 proteins). The HLIG-1 polypeptides include the polypeptides of SEQ ID NOS:2 and 4; as well as polypeptides comprising the amino acid sequence of SEQ ID NO:2; and polypeptides comprising the amino acid sequence which have at least 80% identity to that of SEQ ID NO:2 over its entire length, and still more preferably at least 90% identity, and even still more preferably at least 95% identity to SEQ ID NO: 2. Furthermore, those with at least 97-99% are highly preferred. Also included within HLIG-1 polypeptides are polypeptides having the amino acid sequence which have at least 80% identity to the polypeptide having the amino acid sequence of SEQ ID NO: 2 over its entire length, and still more preferably at least 90% identity, and even still more preferably at least 95% identity to SEQ ID NO: 2. Furthermore, those with at least 97-99% are highly preferred. Preferably HLIG-1 polypeptides exhibit at least one biological activity of the receptor.

The HLIG-1 polypeptides may be in the form of the "mature" protein or may be a part of a larger protein such as a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

Fragments of the HLIG-1 polypeptides are also included in the invention. A fragment is a polypeptide having an amino acid sequence that entirely is the same as part, but not all, of the amino acid sequence of the aforementioned HLIG-1 polypeptides. As with HLIG-1 polypeptides, fragments may be "free-standing," or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 2140, 41-60, 61-80, 81-100, and 101 to the end of HLIG-1 polypeptide. In this context "about" includes the particularly recited ranges larger or smaller by several, 5, 4, 3, 2 or 1 amino acid at either extreme or at both extremes.

Preferred fragments include, for example, truncation polypeptides having the amino acid sequence of HLIG-1 polypeptides, except for deletion of a continuous series of residues that includes the amino terminus, or a continuous series of residues that includes the carboxyl terminus or deletion of two continuous series of residues, one including the amino terminus and one including the carboxyl terminus. Also preferred are fragments characterized by structural or functional attributes such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Other preferred fragments are biologically active fragments. Biologically active fragments are those that mediate receptor activity, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also included are those that are antigenic or immunogenic in an animal, especially in a human.

Preferably, all of these polypeptide fragments retain the biological activity of the receptor, including antigenic activity. Among the most preferred fragment is that having the amino acid sequence of SEQ ID NO: 4. Variants of the defined sequence and fragments also form part of the present invention. Preferred variants are those that vary from the referents by conservative amino acid substitutions--i.e., those that substitute a residue with another of like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination.

The HLIG-1 polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

Polynucleotides of the Invention

Another aspect of the invention relates to HLIG-1 polynucleotides. HLIG-1 polynucleotides include isolated polynucleotides which encode the HLIG-1 polypeptides and fragments, and polynucleotides closely related thereto. More specifically, HLIG-1 polynucleotide of the invention include a polynucleotide comprising the nucleotide sequence contained in SEQ ID NO:1 encoding a HLIG-1 polypeptide of SEQ ID NO: 2, and polynucleotides having the particular sequences of SEQ ID NOS: 1 and 3. HLIG-1 polynucleotides further include a polynucleotide comprising a nucleotide sequence that has at least 80% identity over its entire length to a nucleotide sequence encoding the HLIG-1 polypeptide of SEQ ID NO:2, and a polynucleotide comprising a nucleotide sequence that is at least 80% identical to that of SEQ ID NO:1 over its entire length. In this regard, polynucleotides at least 90% identical are particularly preferred, and those with at least 95% are especially preferred. Furthermore, those with at least 97% are highly preferred and those with at least 98-99% are most highly preferred, with at least 99% being the most preferred. Also included under HLIG-1 polynucleotides are a nucleotide sequence which has sufficient identity to a nucleotide sequence contained in SEQ ID NO:1 to hybridize under conditions useable for amplification or for use as a probe or marker. The invention also provides polynucleotides which are complementary to such HLIG-1 polynucleotides.

HLIG-1 of the invention is structurally related to other proteins of the immunoglobulin superfamily, as shown by the results of sequencing the cDNA encoding human HLIG-1. The cDNA sequence of SEQ ID NO:1 contains an open reading frame (nucleotide number 25 to 3327) encoding a polypeptide of 1101 amino acids of SEQ ID NO:2. The amino acid sequence of Table 1 (SEQ ID NO:2) has about 80.3% identity (using Fasta) in 1101 amino acid residues with mouse LIG-1 (Y. Suzuki et al., J. Biol. Chem. 271:22522-22527, 1996). Furthermore, HLIG-1 is 35.5% identical to rat insulin-like growth factor binding protein over 285 amino acid residues (J. Dai et al., Biochem Biophys. Res. Commun. 188: 304-309, 1992), 30.4% identical to drosophila slit protein over 203 amino acid residues (J. M. Rothberg et al., Genes Dev. 4:2169-2187, 1990) and 32.3% identical to D.melanogaster peroxidasin over 133 amino acid residues (R. E. Nelson et al., EMBO J. 13:3438-3447, 1994). The nucleotide sequence of Table 1 (SEQ ID NO: 1) has about 77.9% identity (using Fasta) in 3577 nucleotide residues with mouse lig-1 gene (Y. Suzuki et al., J. Biol. Chem. 271:22522-22527, 1996). Furthermore, HLIG-1 gene is 86.1% identical to rat CHOT1 gene over 468 nucleotide base residues (W. Mayser et al., FEBS Lett. 305:31-36, 1992). Thus, HLIG-1 polypeptides and polynucleotides of the present invention are expected to have, inter alia, similar biological functions/properties to their homologous polypeptides and polynucleotides, and their utility is obvious to anyone skilled in the art.

TABLE 1.sup.a__________________________________________________________________________ 1 GCTTCGCGGC GCGTTCCAGA CAAGATGGCG CGGCCGGTCC GGGGAGGGCT - 51 CGGGGCCCCG CGCCGCTCGC CTTGCCTTCT CCTTCTCTGG CTGCTTTTGC - 101 TTCGGCTGGA GCCGGTGACC GCCGCGGCCG GCCCGCGGGC GCCCTGCGCG - 151 GCCGCCTGCA CTTGCGCTGG GGACCCCTGC ACTTGCGCTG GGGACTCGCT - 201 GGACTGCGGT GGGCGCGGGC TGGCTGCGTT GCCCGGGGAC CTGCCCTCCT - 251 GGACGCGGAG CCTAAACCTG AGTTACAACA AACTCGCTGA GATTGACCCT - 301 GCTGGTTTTG AGGACTTGCC GAACCTACAG GAAGTGTACC TCAATAATCA - 351 TGAGTTGACA GCGGTAGCAT CACTGGGCGC TGGTTCATCA CAAGTAGTCG - 401 CTCTCTTTCT GCAGCAGCAA CAGAATCGCA GCCTCGACGG GAGCCAGCTG - 451 AAGGCCTACC TCTCCCTAGA AGTGTTAGAT CTGAAACTGA ACAACATCAC - 501 GGAAGTGCGG AACACCTACT TTCCACACGG ACCGCCTATA AAGGAGCTCA - 551 ACCTGGCAGG CAATCGGATT GGCACCCTGG AGTTGGGAGC ATTTGATGGT - 601 CTGTCACGGT CGCTGCTAAC TCTTCGCCTG AGCAAAAACA GGATCACCCA - 651 GCTTCCTGTA AGAGCATTCA AGCTACCCAG GCTGACACAA CTGGACCTCA - 701 ATCGGAACAG GATTCGGCTG ATAGAGGGCC TCACCTTCCA GGGGCTCAAC - 751 AGCTTGGAGG TGCTGAAGCT TCAGCGAAAC AACATCAGCA AACTGACAGA - 801 TGGGGCCTTC TGGGGACTGT CCAAAATGCA TGTGCTGCAC CTGGAGTACG - 851 ACAGCCTGGT AGAAGTGAAC AGCGGCTCGC TCTACGGCCT CACGGCCCTG - 901 CATCAGCTCC ACCTCAGCAA CAATTCCATC GCTCGCATTC ACCGCAAGGG - 951 CTGGAGCTTC TGCCAGAAGC TGCATGAGTT GGTCCTGTCC TTCAACAACC - 1001 TGACACGGCT GGACGAGGAG AGCCTGGCCG AGCTGAGCAG CCTGAGTGTC - 1051 CTGCGTCTCA GCCACAATTC CATCAGCCAG ATTGCGGAGG GTGCCTTCAA - 1101 GGGACTCAGG AGCCTGCGAG TCTTGGATCT GGACCATAAC GAGATTTCGG - 1151 GCACAATAGA GGACACGAGC GGCGCCTTCT CAGGGCTCGA ATTCGGCCAC - 1201 AGCAAGCTGA CTCTGTTTGG AAACAAGATC AAGTCTGTGG CTAAGAGAGC - 1251 ATTCTCGGGG CTGGAAGGCC TGGAGCACCT GAACCTTGGA GGGAATGCGA - 1301 TCAGATCTGT CCAGTTTGAT GCCTTTGTGA AGATGAAGAA TCTTAAAGAG - 1351 CTCCATATCA GCAGCGACAG CTTCCTGTGT GACTGCCAGC TGAAGTGGCT - 1401 GCCCCCGTGG CTAATTGGCA GGATGCTGCA GGCCTTTGTG ACAGCCACCT - 1451 GTGCCCACCC AGAATCACTG AAGGGTCAGA GCATTTTCTC TGTGCCACCA - 1501 GAGAGTTTCG TGTGCGATGA CTTCCTGAAG CCACAGATCA TCACCCAGCC - 1551 AGAAACCACC ATGGCTATGG TGGGCAAGGA CATCCGGTTT ACATGCTCAG - 1601 CAGCCAGCAG CAGCAGCTCC CCCATGACCT TTGCCTGGAA GAAAGACAAT - 1651 GAAGTCCTGA CCAATGCAGA CATGGAGAAC TTTGTCCACG TCCACGCGCA - 1701 GGACGGGGAA GTGATGGAGT ACACCACCAT CCTGCACCTC CGTCAGGTCA - 1751 CTTTCGGGCA CGAGGGCCGC TACCAATGTG TCATCACCAA CCACTTTGGC - 1801 TCCACCTATT CACATAAGGC CAGGCTCACC GTGAATGTGT TGCCATCATT - 1851 CACCAAAACG CCCCACGACA TAACCATCCG GACCACCACC GTGGCCCGCC - 1901 TCGAATGTGC TGCCACAGGT CACCCAAACC CTCAGATTGC CTGGCAGAAG - 1951 GATGGAGGCA CGGATTTCCC CGCTGCCCGT GAGCGACGCA TGCATGTCAT - 2001 GCCGGATGAC GACGTGTTTT TCATCACTGC TGTGAAAATA GATGACGCAG - 2051 GGGTTTACAG CTGTACTGCT CAGAACTCAG CCGGTTCTAT TTCAGCTAAT - 2101 GCCACCCTGA CTGTCCTAGA GACCCCATCC TTGGTGGTCC CCTTGGAAGA - 2151 CCGTGTGGTA TCTGTGGGAG AAACAGTGGC CCTCCAATGC AAAGCCACGG - 2201 GGAACCCTCC GCCCCGCATC ACCTGGTTCA AGGGGGACCG CCCGCTGAGC - 2251 CTCACTGAGC GGCACCACCT GACCCCTGAC AACCAGCTCC TGGTGGTTCA - 2301 GAACGTGGTG GCAGAGGATG CGGGCCGATA TACCTGTGAG ATGTCCAACA - 2351 CCCTGGGCAC GGAGCGAGCT CACAGCCAGC TGAGCGTCCT GCCCGCAGCA - 2401 GGCTGCAGGA AGGATGGGAC CACGGTAGGC ATCTTCACCA TTGCTGTCGT - 2451 GAGCAGCATC GTCCTGACGT CACTGGTCTG GGTGTGCATC ATCTACCAGA - 2501 CCAGGAAGAA GAGTGAAGAG TACAGTGTCA CCAACACAGA TGAAACCGTC - 2551 GTGCCACCAG ATGTTCCAAG CTACCTCTCT TCTCAGGGGA CCCTTTCTGA - 2601 CCGACAAGAA ACCGTGGTCA GGACCGAGGG TGGCCCTCAG GCCAATGGGC - 2651 ACATTGAGAG CAATGGTGTG TGTCCAAGAG ATGCAAGCCA CTTTCCAGAG - 2701 CCCGACACTC ACAGCGTTGC CTGCAGGCAG CCAAAGCTCT GTGCTGGGTC - 2751 TGCGTATCAC AAAGAGCCGT GGAAAGCGAT GGAGAAAGCT GAAGGGACAC - 2801 CTGGGCCACA TAAGATGGAA CACGGTGGCC GGGTCGTATG CAGTGACTGC - 2851 AACACCGAAG TGGACTGTTA CTCCAGGGGA CAAGCCTTCC ACCCCCAGCC - 2901 TGTGTCCAGA GACAGCGCAC AGCCAAGTGC GCCAAATGGC CCGGAGCCGG - 2951 GTGGGAGTGA CCAAGAGCAT TCTCCACATC ACCAGTGCAG CAGGACTGCC - 3001 GCTGGGTCCT GCCCCGAGTG CCAAGGGTCG CTCTACCCCA GTAACCACGA - 3051 TAGAATGCTG ACGGCTGTGA AGAAAAAGCC AATGGCATCT CTAGATGGGA - 3101 AAGGGGATTC TTCCTGGACT TTAGCAAGGT TGTATCACCC GGACTCCACA - 3151 GAGCTACAGC CTGCATCTTC ATTAACTTCA GGCAGTCCAG AGCGCGCGGA - 3201 AGCCCAGTAC TTGCTTGTTT CCAATGGCCA CCTCCCCAAA GCATGTGACG - 3251 CCAGTCCCGA GTCCACGCCA CTGACAGGAC AGCTCCCCGG GAAACAGAGG - 3301 GTGCCACTGC TGTTGGCACC AAAAAGCTAG GTTTTGTCTA CCTCAGTTCT - 3351 TGTCATACCA ATCTCTACGG GAAAGAGAGG TAGGAGAGGC TGCGAGGAAG - 3401 CTTGGGTTCA AGCGTCACTC ATCTGTACAT AGTTGTAACT CCCATGTGGA - 3451 GTATCAGTCG CTCACAGGAC TTGGATCTGA AGCACAGTAA ACGCAAGAGG - 3501 GGATTTGTGT ACAAAAGGCA AAAAAAGTAT TTGATATCAT TGTACATAAG - 3551 AGTTTTCAGA GATTTCATAT ATATCTTTTA CAGAGGCTAT TTTAATCTTT - 3601 AGTGCATGGT TAACAGAAAA AAATTATACA ATTTTGACAA TATTATTTTT - 3651 CGTATCAGGT TGCTGTTTAA TTTTGGAGGG GGTGGGGAAA TAGTTCTGGT - 3701 GCCTTAACGC ATGGCTGGAA TTTATAGAGG CTACAACCAC ATTTGTTCAC - 3751 AGGAGTTTTT GGTGCGGGGT GGGAAGGATG GAAGGCCTTG GATTTATATT - 3801 GCACTTCATA GACCCCTAGG CTGCTGTGCG GTGGGACTCC ACATGCGCCG - 3851 GAAGGAGCTT CAGGTGAGCA CTGCTCATGT GTGGATGCCC CTGCAACAGG - 3901 CTTCCCTGTC TGTAGAGCCA GGGGTGCAAG TGCCATCCAC ACTTGCAGTG - 3951 AATGGCTTTT CCTTTTAGGT TTAAGTCCTG TCTGTCTGTA AGGCGTAGAA - 4001 TCTGTCCGTC TGTAAGGCGT AGAATGAGGG TTGTTAATCC ATCACAAGCA - 4051 AAAGGTCAGA ACAGTTAAAC ACTGCCTTTC CTCCTCCTCT TATTTTATGA - 4101 TAAAAGCAAA TGTGGCCTTC TCAGTATCAT TCGATTGCTA TTTGAGACTT - 4151 TTAAATTAAG GTAAAGGCTG CTGGTGTTGG TACCTGTGGA TTTTTCTATA - 4201 CTGATGTTTT CGTTTTGCCA ATATAATGAG TATTACATTG GCCTTGGGGG - 4251 ACAGAAAGGA GGAAGTTCTG ACTTTTCAGG GCTACCTTAT TTCTACTAAG - 4301 GACCCAGAGC AGGCCTGTCC ATGCCATTCC TTCGCACAAG ATGAAACTGA - 4351 GCTGGGACTG GAAAGGACAG CCCTTGACCT GGGTTTCTGG GTATAATTTG - 4401 CACTTTTGAG ACTGGTAGCT AACCATCTTA TGAGTGCCAA TGTGTCATTT - 4451 AGTAAAACTT AAATAGAAAC AAGGTCCTTC AAATGTTCCT TTGGCCAAAA - 4501 GCTGAAGGGA GTTACTGAGA AAATAGTTAA CAATTACTGT CAGGTGTCAT - 4551 CACTGTTCAA AAGGTAAGCA CATTTAGAAT TTTGTTCTTG ACAGTTAACT - 4601 GACTAATCTT ACTTCCACAA AATATGTGAA TTTGCTGCTT CTGAGAGGCA - 4651 ATGTGAAAGA GGGAGTATTA CTTTTATGTA CAAAGTTATT TATTTATAGA - 4701 AATTTTGGTA CAGTGTACAT TGAAAACCAT GTAAAATATT GAAGTGTCTA - 4751 ACAAATGGCA TTGAAGTGTC TTTAATAAAG GTTCATTTAT AAAAGTCAAA - 4801 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAA__________________________________________________________________________ .sup.a A nucleotide sequence of a human HLIG1 (SEQ ID NO: 1). TABLE 2.sup.b__________________________________________________________________________ 1 MARPVRGGLG APRRSPCLLL LWLLLLRLEP VTAAAGPRAP CAAACTCAGD - 51 PCTCAGDSLD CGGRGLAALP GDLPSWTRSL NLSYNKLAEI DPAGFEDLPN - 101 LQEVYLNNHE LTAVASLGAG SSQVVALFLQ QQQNRSLDGS QLKAYLSLEV - 151 LDLNLNNITE VRNTYFPHGP PIKELNLAGN RIGTLELGAF DGLSRSLLTL - 201 RLSKNRITQL PVRAFKLPRL TQLDLNRNRI RLIEGLTFQG LNSLEVLKLQ - 251 RNNISKLTDG AFWGLSKMHV LHLEYDSLVE VNSGSLYGLT ALHQLHLSNN - 301 SIARIHRKGW SFCQKLHELV LSFNNLTRLD EESLAELSSL SVLRLSHNSI - 351 SHIAEGAFKG LRSLRVLDLD HNEISGTIED TSGAFSGLEF GHSKLTLFGN - 401 KIKSVAKRAF SGLEGLEHLN LGGNAIRSVG FDAFVKMKNL KELHISSDSF - 451 LCDCQLKWLP PWLIGRMLQA FVTATCAHPE SLKGQSIFSV PPESFVCDDF - 501 LKPQIITQPE TTMAMVGKDI RFTCSAASSS SSPMTFAWKK DNEVLTNADM - 551 ENFVHVHAQD GEVMEYTTIL HLRQVTFGHE GRYQCVITNH FGSTYSHKAR - 601 LTVNVLPSFT KTPHDITIRT TTVARLECAA TGHPNPQIAW QKDGGTDFPA - 651 ARERRMHVMP DDDVFFITDV KIDDAGVYSC TAQNSAGSIS ANATLTVLET - 701 PSLVVPLEDR VVSVGETVAL QCKATGNPPP RITWFKGDRP LSLTERHHLT - 751 PDNQLLVVQN VVAEDAGRYT CEMSNTLGTE RAHSQLSVLP AAGCRKDGTT - 801 VGIFTIAVVS SIVLTSLVWV CIIYQTRKKS EEYSVTNTDE TVVPPDVPSY - 851 LSSQGTLSDR QETVVRTEGG PQANGHIESN GVCPRDASHF PEPDTHSVAC - 901 RQPKLCAGSA YHKEPWKAME KAEGTPGPHK MEHGGRVVCS DCNTEVDCYS - 951 RGQAFHPQPV SRDSAQPSAP NGPEPGGSDQ EHSPHHQCSR TAAGSCPECQ - 1001 GSLYPSNHDR MLTAVKKKPM ASLDGKGDSS WTLARLYHPD STELQPASSL - 1051 TSGSPERAEA QYLLVSNGHL PKACDASPES TPLTGQLPGK QRVPLLLAPK - 1101 S__________________________________________________________________________ .sup.b An amino acid sequence of a human HLIG1 (SEQ ID NO: 2).

One polynucleotide of the present invention encoding HLIG-1 may be obtained using standard cloning and screening, from a cDNA library derived from mRNA in cells of human brain, ovary, immune system, using the expressed sequence tag (EST) analysis (Adams, M. D., et al. Science (1991)252:1651-1656; Adams, M. D. et al., Nature, (1992) 355:632-634; Adams, M. D., et al., Nature (1995) 377 Supp:3-174). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

The nucleotide sequence encoding HLIG-1 polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in Table 1 (nucleotide number 25 to 3327 of SEQ ID NO:1), or it may be a sequence, which as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2.

When the polynucleotides of the invention are used for the recombinant production of HLIG-1 polypeptide, the polynucleotide may include the coding sequence for the mature polypeptide or a fragment thereof, by itself, the coding sequence for the mature polypeptide or fragment in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence which facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz et al., Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

Further preferred embodiments are polynucleotides encoding HLIG-1 variants comprising the amino acid sequence of HLIG-1 polypeptide of Table 2 (SEQ ID NO:2) in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acid residues are substituted, deleted or added, in any combination. Among the preferred polynucleotides of the present invention is contained in Table 3 (SEQ ID NO: 3) encoding the amino acid sequence of Table 4 (SEQ ID NO: 4).

TABLE 3.sup.c__________________________________________________________________________ 1 ACGCCCCACG ACATAACCAT CCGGACCACC ACCGTGGCCC GCCTCGAATG - 51 TGCTGCCACA GGTCACCCAA ACCCTCAGAT TGCCTGGCAG AAGGATGGAG - 101 GCACGGATTT CCCCGCTGCC CGTGAGCGAC GCATGCATGT CATGCCGGAT - 151 GACGACGTGT TTTTCATCAC TGATGTGAAA ATAGATGACG CAGGGGTTTA - 201 CAGCTGTACT GCTCAGAACT CAGCCGGTTC TATTgnTACA GCTAATGCCA - 251 CCCTGACTGT CCTAGAGACC CCATCCTTGG TGGTCCCCTT GGAAGACCGT - 301 GTGGTATCTG TGGGAGAAAC AGTGGCCCTC CAATGCAAAG CCACGGGGAA - 351 CCCTCTGCCC CGCATCACCT GGTTCAAGGG GGACCTCCCG CTGAAGACCT - 401 GCACTGAGCC GGGCACCACT TGACCCCTGA CAACCAGCTC CTGGTGGTTC - 451 AGAACGTGGT GGGCAGAGGA TGCGGGCCGA TATACCTGTG AGATGTCCAA - 501 CACCCTGGGC ACGGAGCGAG CTCACAGTCC AGCTGAGCGT CCCTGCCCGC - 551 AGACAGGCTG CAGGTAAGGA TTGGAACCAC GGTTGGCATC TTCCACCATT - 601 GACTGTCGTG AGCCAGCATC GTCCTGACGT CACTGGATCT TGGGTTTGGA - 651 TTCATCTATC AGAACCAGGA AGAAGAGTGA AGAGTTACAG TTTTCCCCAC - 701 AACCAGGTTG AAAACCGTTG GTGGCACCAG ATGTTCCAAG CTACCTCTCT - 751 TCTCAGGGGA CCCTTTCTGA CCGACAAGAA ACCGTGGTCC AGGACCGAGG - 801 GTTCGGCCCT GAGGGCAATG GGCACATTGA GAGCAATGGT GTGTGTCCAA - 851 GAGATGCAAG CCACTTTCCA GAGCCCGACA CTCACAGCGT TGCCTGCAGG - 901 CAGCCAAAGC TCTGTGCTGG GTCTGGGTAT CACAAAGAGC CGTGGAAAGC - 951 GATGGAGAAA GCTGGAAGGG ACACCTGGGC CACATGAAGA TGGGAAGACG - 1001 GTGGACCGGG TCGTATGCAG TGACTGCAAC ACCGAAGTGG CAGAGACTGT - 1051 TTACTCCAGG GGAACAAGCC TTCCACCCCC AGCCTGTGTC CAGAGGACAG - 1101 TGCACAGCCA AGTGGGCCAA AATGGTCCCG GAGCCGGGTG GGGAAGTGAC - 1151 CAAGAGGCAT TCTTCCACAT CACCATTGCA GAGGATTGCA CGTTGGGTCC - 1201 TGCCCCGAGT GGCCCAGGGT TGTTTTTAAC CCCATTAACC ACGTTAGAAT - 1251 GTTTTTTGAC GGTTTTTGAA GGAAAAGCCA TTGGCATCTC TAGATGGGAA - 1301 AGGGGATTCT TCCTGGACTT TAGCAAGGTT GTATCACCCG GACTCCACAG - 1351 AGCTACAGCC TGCATCTTCA TTAACTTCAG GCAGTCCAGA GCGCGCGGAA - 1401 GCCCAGTACT TGCTTGTTTC CAATGGCCAC CTCCCCAAAG CATGTGACGC - 1451 CAGTCCCGAG TCCACGCCAC TGACAGGACA GCTCCCCGGG AAACAGAGGG - 1501 TGCCACTGCT GTTGGCACCA AAAAGCTAGG TTTTGTCTAC CTCAGTTCTT - 1551 GGTCATACCA ATCTCTACGG GAAAGAGAGG TAGGAGAGGC TGCGAGGAAG - 1601 CTTGGGTTCA AGCGTCACTC ATCTGTACAT AGTTGTAACT CCCATGTGGA - 1651 GTATCCAGTC GTTCACAGGA CTTGGGATCT GAAGCACAGT AAACGCAAGA - 1701 GGGGGATTTG TGTACCAAAA GGCAAAAAAA AGTATTTGAT ATCCATTGTA - 1751 CCATAAGGGT TTTCAGGGGT TTCATATATA TCCTTTTAAC AGAGGTTATT - 1801 TTAATCTTTA GTGCATGGTT AACCGGAAAA AATTTTTCCA TTTTGGCCAT - 1851 TTTATTTTTC CGTATCCAGG TTGCTGTTTA ATTTTGGAGG GGGTTGGGGA - 1901 AATAGTTCTG GTGCCTTAAC GCATGGCTGG GAATTTATAG AGGCTACAAC - 1951 CACATTTGTT CACAGGAAGT TTTTGGTGCG GGGTGGGAAG GATGGAAGGC - 2001 CTTGGAATTT ATATTGCACT TCATAGACCC CTAGGCTGCT GTGCGGTGGG - 2051 ACTCCACATG CGCCCGGAAG GAGCTTTCAG GTGAGCACTG CTCATGTGTG - 2101 GATGCCCCTG CAACAGGCTT CCCTGTCTGT AGAGCCAGGG GTGCAAGTGC - 2151 CCATCCACAC TTGCAGTGAA TGGCTTTTCC TTTTAGTTTT AAGTCCTGTC - 2201 TGTTTTTAAG GCGTAGGATT TGTCCTTCTG TAAGGCGTGG AATGAGGGTT - 2251 GTTAATCCAT CACAAGCAAA AGGTCCGAAC CGTTAAACAC TGCCTTTCCT - 2301 CCTCCTTATT TTGGTTCCCT TATTTTATGT TAAAAGCAAA TGTGGCCTTC - 2351 TCAGTATCAT TCGATTGCTA TTTGAGACTT TTAAATTAAG GTAAAGGCTG - 2401 CTGGTGTTGG TACCTGTGGA TTTTTCTATA CTGATGTTTT CGTTTTGCCA - 2451 ATATAATGAG TATTACATTG GCCTTGGGGG ACAGAAAGGA GGAAGTTCTG - 2501 ACTTTTCAGG GCTACCTTAT TTCTACTAAG GACCCAGAGC AGGCCTGTCC - 2551 ATGCCATTCC TTCGCACAGA TGAAACTGAG CTGGGACTGG AAAGGACAGC - 2601 CCTTGACCTG GGTTCTGGGT ATAATTTGCA CTTTTGAGAC TGGTAGCTAA - 2651 CCATCTTATG AGTGCCAATG TGTCATTTAG TAAAACTTAA ATAGAAACAA - 2701 GGTCCTTCAA ATGTTCCTTT GGCCAAAAGC TGAAGGGAGT TACTGAGAAA - 2751 ATAGTTAACA ATTACTGTCA GGTGTCATCA CTGTTCAAAA GGTAAGCACA - 2801 TTTAGAATTT TGTTCTTGAC AGTTAACTGA CTAATCTTAC TTCCACAAAA - 2851 TATGTGAATT TGCTGCTTCT GAGAGGCAAT GTGAAAGAGG GAGTATTACT - 2901 TTTATGTACA AAGTTATTTA TTTATAGAAA TTTTGGTACA GTGTACATTG - 2951 AAAACCATGT AAAATATTGA AGTGTCTAAC AAATGGCATT GAAGTGTCTT - 3001 TAATAAAGGT TCATTTATAA ATGTCAAAAT AANNNNAAGT TATTTATTTA - 3051 TAGAAATTTT GGTACAGTGT ACATTGAAAA CCATGTAAAA TATTGAAGTG - 3101 TNCTAACAAA TGGCATTGAA GTGTNCTTTA ATAAAGGTTC ATTTATAAAT - 3151 GTCNNAAAA__________________________________________________________________________ .sup.c A partial nucleotide sequence of a human HLIG1 (SEQ ID NO: 3). TABLE 4.sup.d__________________________________________________________________________ 1 TPHDITIRTT TVARLECAAT GHPNPQIAWQ KDGGTDFPAA RERRMHVMPD - 51 DDVFFITDVK IDDAGVYSCT AQNSAGSIXT ANATLTVLET PSLVVPLEDR - 101 VVSVGETVAL QCKATGNPLP RITWFKGDLP LKTCTEPGTT__________________________________________________________________________ .sup.d A partial amino acid sequence of a human HLIG1 (SEQ ID NO: 4).

The present invention further relates to polynucleotides that hybridize to the herein above-described sequences. In this regard, the present invention especially relates to polynucleotides which hybridize under stringent conditions to the herein above-described polynucleotides. As herein used, the term "stringent conditions" means hybridization will occur only if there is at least 80%, and preferably at least 90%, and more preferably at least 95%, yet even more preferably 97-99% identity between the sequences.

Polynucleotides of the invention, which are identical or sufficiently identical to a nucleotide sequence contained in SEQ ID NO:1 or a fragment thereof, may be used as hybridization probes for cDNA and genomic DNA, to isolate full-length cDNAs and genomic clones encoding HLIG-1 and to isolate cDNA and genomic clones of other genes (including genes encoding homologs and orthologs from species other than human) that have a high sequence similarity to the HLIG-1 gene. Such hybridization techniques are known to those of skill in the art. Typically these nucleotide sequences are 80% identical, preferably 90% identical, more preferably 95% identical to that of the referent. The probes generally will comprise at least 15 nucleotides. Preferably, such probes will have at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will range between 30 and 50 nucleotides.

In one embodiment, to obtain a polynucleotide encoding HLIG-1 polypeptide, including homologs and orthologs from species other than human, comprises the steps of screening an appropriate library under stingent hybridization conditions with a labeled probe having the SEQ ID NO:1 or a fragment thereof (including that of SEQ ID NO: 3), and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to those of skill in the art. Stringent hybridization conditions are as defined above or alternatively conditions under overnight incubation at 42.degree. C. in a solution comprising: 50% formamide, 5.times. SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5.times. Denhardt's solution, 10% dextran sulfate, and 20 microgram/mil denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1.times. SSC at about 65.degree. C.

The polynucleotides and polypeptides of the present invention may be employed as research reagents and materials for discovery of treatments and diagnostics to animal and human disease.

Vectors, Host Cells, Expression

The present invention also relates to vectors which comprise a polynucleotide or polynucleotides of the present invention, and host cells which are genetically engineered with vectors of the invention and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al., BASIC METHODS IN MOLECULAR BIOLOGY (1986) and Sambrook et al., MOLECULAR CLONING. A LABORATORY MANUAL, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) such as calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as streptococci, staphylococci, E. coli, Streptomyces and Bacillus subtilis cells; fungal cells, such as yeast cells and Aspergillus cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, HeLa, C 127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used. Such systems include, among others, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector suitable to maintain, propagate or express polynucleotides to produce a polypeptide in a host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL (supra).

For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the desired polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If the HLIG-1 polypeptide is to be expressed for use in screening assays, generally, it is preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If HLIG-1 polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide; if produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

HLIG-1 polypeptides can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.

Diagnostic Assays

This invention also relates to the use of HLIG-1 polynucleotides for use as diagnostic reagents. Detection of a mutated form of HLIG-1 gene associated with a dysfunction will provide a diagnostic tool that can add to or define a diagnosis of a disease or susceptibility to a disease which results from under-expression, over-expression or altered expression of HLIG-1. Individuals carrying mutations in the HLIG-1 gene may be detected at the DNA level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled HLIG-1 nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing. See, e.g., Myers et al., Science (1985) 230:1242. Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method. See Cotton et al., Proc Natl Acad Sci USA (1985) 85: 4397-4401. In another embodiment, an array of oligonucleotides probes comprising HLIG-1 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability. (See for example: M. Chee et al., Science, Vol 274, pp 610-613 (1996)).

The diagnostic assays offer a process for diagnosing or determining a susceptibility to neurological disorders such as Alzheimer's disease, multiple sclerosis and abnormal neural development; endocrine disorders such as diabetes; and heart disease through detection of mutation in the HLIG-1 gene by the methods described.

In addition, neurological disorders such as Alzheimer's disease, multiple sclerosis and abnormal neural development; endocrine disorders such as diabetes; and heart disease, can be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of HLIG-1 polypeptide or HLIG-1 mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as an HLIG-1, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagonostic kit for a disease or suspectability to a disease, particularly neurological disorders such as Alzheimer's disease, multiple sclerosis and abnormal neural development; endocrine disorders such as diabetes; and heart disease, which comprises:

(a) a HLIG-1 polynucleotide, preferably the nucleotide sequence of SEQ ID NO: 1, or a fragment thereof; (b) a nucleotide sequence complementary to that of (a); (c) a HLIG-1 polypeptide, preferably the polypeptide of SEQ ID NO: 2, or a fragment thereof; or (d) an antibody to a HLIG-1 polypeptide, preferably to the polypeptide of SEQ ID NO: 2. It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Chromosome Assays

The nucleotide sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).

The differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease. Antibodies

The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them can also be used as immunogens to produce antibodies immunospecific for the HLIG-1 polypeptides. The term "immunospecific" means that the antibodies have substantiall greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against the HLIG-1 polypeptides can be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a nonhuman, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., Nature (1975) 256:495497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., Immunology Today (1983) 4:72) and the EBV-hybridoma technique (Cole et al., MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp. 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies (U.S. Pat. No. 4,946,778) can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms including other mammals, may be used to express humanized antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography.

Antibodies against HLIG-1 polypeptides may also be employed to treat neurological disorders such as Alzheimer's disease, multiple sclerosis and abnormal neural development; endocrine disorders such as diabetes; and heart disease, among others.

Vaccines

Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with HLIG-1 polypeptide, or a fragment thereof, adequate to produce antibody and/or T cell immune response to protect said animal from neurological disorders such as Alzheimer's disease, multiple sclerosis and abnormal neural development; endocrine disorders such as diabetes; and heart disease, among others. Yet another aspect of the invention relates to a method of inducing immunological response in a mammal which comprises, delivering HLIG-1 polypeptide via a vector directing expression of HLIG-1 polynucleotide in vivo in order to induce such an immunological response to produce antibody to protect said animal from diseases.

Further aspect of the invention relates to an immunological/vaccine formulation (composition) which, when introduced into a mammalian host, induces an immunological response in that mammal to a HLIG-1 polypeptide wherein the composition comprises a HLIG-1 polypeptide or HLIG-1 gene. The vaccine formulation may further comprise a suitable carrier. Since HLIG-1 polypeptide may be broken down in the stomach, it is preferably administered parenterally (including subcutaneous, intramuscular, intravenous, intradermal etc. injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation instonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Screening Assays

The HLIG-1 polypeptide of the present invention may be employed in a screening process for compounds which bind the receptor and which activate (agonists) or inhibit activation of (antagonists) the receptor polypeptide of the present invention. Thus, polypeptides of the invention may also be used to assess the binding of small molecule substrates and ligands in, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics. See Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).

HLIG-1 polypeptides are responsible for many biological functions, including many pathologies. Accordingly, it is desirous to find compounds and drugs which stimulate HLIG-1 on the one hand and which can inhibit the function of HLIG-1 on the other hand. In general, agonists are employed for therapeutic and prophylactic purposes for such conditions as neurological disorders such as Alzheimer's disease, multiple sclerosis and abnormal neural development; endocrine disorders such as diabetes; and heart disease. Antagonists may be employed for a variety of therapeutic and prophylactic purposes for such conditions as neurological disorders such as Alzheimer's disease, multiple sclerosis and abnormal neural development; endocrine disorders such as diabetes; and heart disease.

In general, such screening procedures involve producing appropriate cells which express the receptor polypeptide of the present invention on the surface thereof Such cells include cells from mammals, yeast, Drosophila or E. coli. Cells expressing the receptor (or cell membrane containing the expressed receptor) are then contacted with a test compound to observe binding, or stimulation or inhibition of a functional response.

The assays may simply test binding of a candidate compound wherein adherence to the cells bearing the receptor is detected by means of a label directly or indirectly associated with the candidate compound or in an assay involving competition with a labeled competitor. Further, these assays may test whether the candidate compound results in a signal generated by activation of the receptor, using detection systems appropriate to the cells bearing the receptor at their surfaces. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed.

Further, the assays may simply comprise the steps of mixing a candidate compound with a solution containing a HLIG-1 polypeptide to form a mixture, measuring HLIG-1 activity in the mixture, and comparing the HLIG-1 activity of the mixture to a standard.

The HLIG-1 cDNA, protein and antibodies to the protein may also be used to configure assays for detecting the effect of added compounds on the production of HLIG-1 mRNA and protein in cells. For example, an ELISA may be constructed for measuring secreted or cell associated levels of HLIG-1 protein using monoclonal and polyclonal antibodies by standard methods known in the art, and this can be used to discover agents which may inhibit or enhance the production of HLIG-1 (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues. Standard methods for conducting screening assays are well understood in the art.

Examples of potential HLIG-1 antagonists include antibodies or, in some cases, oligonucleotides or proteins which are closely related to the ligand of the HLIG-1, e.g., a fragment of the ligand, or small molecules which bind to the receptor but do not elicit a response, so that the activity of the receptor is prevented.

Thus in another aspect, the present invention relates to a screening kit for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, etc. for HLIG-1 polypeptides; or compounds which decrease or enhance the production of HLIG-1 polypeptides, which comprises:

(a) a HLIG-1 polypeptide, preferably that of SEQ ID NO:2; (b) a recombinant cell expressing a HLIG-1 polypeptide, preferably that of SEQ ID NO:2; (c) a cell membrane expressing a HLIG-1 polypeptide; preferably that of SEQ ID NO: 2; or (d) antibody to a HLIG-1 polypeptide, preferably that of SEQ ID NO: 2. It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Prophylactic and Therapeutic Methods

This invention provides methods of treating an abnormal conditions related to both an excess of and insufficient amounts of HLIG-1 activity.

If the activity of HLIG-1 is in excess, several approaches are available. One approach comprises administering to a subject an inhibitor compound (antagonist) as hereinabove described along with a pharmaceutically acceptable carrier in an amount effective to inhibit activation by blocking binding of ligands to the HLIG-1, or by inhibiting a second signal, and thereby alleviating the abnormal condition.

In another approach, soluble forms of HLIG-1 polypeptides still capable of binding the ligand in competition with endogenous HLIG-1 may be administered. Typical embodiments of such competitors comprise fragments of the HLIG-1 polypeptide.

In still another approach, expression of the gene encoding endogenous HLIG-1 can be inhibited using expression blocking techniques. Known such techniques involve the use of antisense sequences, either internally generated or separately administered. See, for example, O'Connor, J Neurochem (1991) 56:560 in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, Fla. (1988). Alternatively, oligonucleotides which form triple helices with the gene can be supplied. See, for example, Lee et al., Nucleic Acids Res (1979) 6:3073; Cooney et al., Science (1988) 241:456; Dervan et al., Science (1991) 251:1360. These oligomers can be administered per se or the relevant oligomers can be expressed in vivo.

For treating abnormal conditions related to an under-expression of HLIG-1 and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates HLIG-1, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene therapy may be employed to effect the endogenous production of HLIG-1 by the relevant cells in the subject. For example, a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells in vivo and expression of the polypeptide in vivo. For overview of gene therapy, see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996).

Formulation and Administration

Peptides, such as the soluble form of HLIG-1 polypeptides, and agonists and antagonist peptides or small molecules, may be formulated in combination with a suitable pharmaceutical carrier. Such formulations comprise a therapeutically effective amount of the polypeptide or compound, and a pharmaceutically acceptable carrier or excipient. Such carriers include but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. Formulation should suit the mode of administration, and is well within the skill of the art. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

Preferred forms of systemic administration of the pharmaceutical compositions include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if properly formulated in enteric or encapsulated formulations, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels and the like.

The dosage range required depends on the choice of peptide, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 .mu.g/kg of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above. Thus, for example, cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide ex vivo, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

EXAMPLES

The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The examples illustrate, but do not limit the invention.

Example 1

Cloning of the cDNA Containing the Complete Protein Coding Region

While there are several methods to obtain the full length cDNA, two are outlined below:

1) The method of Rapid Amplification of cDNA ENDS (RACE) can be utilized to extend the 5' end of incomplete cDNA clones (Frohman et al., Proc. Nat. Acad. Scd, USA 85, 8998-9002 (1988)). Briefly, a specific oligonucleotide complementary to the 5' region of the incomplete clone is annealed to mRNA and used to prime the synthesis of the cDNA strand. Following digestion of the mRNA with RNase H, a poly dC anchor segment is added to the 3' end of the extended cDNA and this region is then amplified by PCR using a set of nested primers positioned at the 5' end of the original cDNA, upstream of the cDNA primer, coupled with the anchor primer. The amplified fragment is cloned into an appropriate plasmid vector and subjected to restriction and sequence analysis. The linkage of the new 5' region with the original cDNA is confirmed by RT-PCR using primers positioned in the new 5' sequence coupled with primers in the original cDNA clone.

2) The polymerase chain reaction can be used to amplify the 5' end of the cDNA from human cDNA libraries using sequential rounds of nested PCR with two sets of primers. One set of antisense primers is specific to the 5' end of the partial cDNA and the other set of primers anneals to a vector specific sequence. The amplified products are cloned into an appropriate vector and subjected to restriction and sequence analysis. The linkage of the new and original sequences is confirmed as in (1) above.

For HLIG-1, most of the cDNA sequence was present in the cDNA clone defined by HGS EST: 231054. The missing 5' end of the 1.8 kb cDNA sequence was isolated by the 5' RACE PCR procedure, using mRNA from the human Daudi B cell line as the template. Assembly of these two DNA fragments generated the full length sequence of the HLIG-1 gene.

Example 2

HLIG-1 is the Human Homologue of Mouse LIG-1

As shown in the alignment below, the complete protein sequence of HLIG-1 exhibits 80.3% identity to the mouse LIG-1 protein and the homology extends throughout the entire protein sequence. This high linear homology demonstrates that HLIG-1 is the human homologue of mouse LIG-1. The extracellular domain contains 15 LRRs flanked by cysteine cluster regions, followed by 3 C2-type Ig-like domains.

(SEQ ID NO:5) .2 -Flanking HLIG-1 1 MARPVRGGLGAPRRSPC LLLLWLLLLRLEPVTAAAGPRA PCAAACTCAGDPCTCAGDSLD .vertline..vertline..vertline..vertline. :.vertline. .vertline..ver tline..vertline..vertl ine..vertline. :.vertline. .vertline ..vertline..vertline.. vertline..vertline..ve rtline..vertline..vert line. .vertline.: :::.vertline..vertline .::.vertline.: .vertline.:.vertline. :::.vertline..vertli ne..vertline..vertline ..vertline.:.vertline. .vertline..vertline. MLIG-1 1 MARPGPGVLG APRLAP-RLLLWLLLLLLQ-WP ESAGAQARPRAPC---AAACTC AGNSLD - LRR 1 LRR 2 HLIG-1 61 CGGRGLAALPGDLPSWTRSLNLSYNKLAEIDPAGFEDLPNLQEVYLNNHELTAVASLGAG .vertline.:.vertline..vertline..vertline..vertline..vertline.:.ver tline..vertline. .vertline..vertline..v ertline..vertline..ver tline..vertline..vertl ine..vertline..vertlin e..vertline..vertline. .vertline..vertline..v ertline.:.vertline.:.v ertline..vertline..ver tline.:.vertline.:.ver tline..vertline..vertl ine..vertline.:.vertli ne..vertline..vertline ..vertline..vertline.. vertline..vertline..ve rtline.::.vertline..ve rtline..vertline..vert line.::.vertline..vert line..vertline.:: MLIG-1 56 CSGRGLATLP RDLPSWTRSLNLSYNRLSEIDS AAFEDLTNLQEVYLNSNELTAI PSLGTA - LRR 3 LRR 4 HLIG-1 121 SSQVVALFLQQQQNRSLDGSQLKAYLSLEVLDLNLNNITEVRNTYFPHGPPIKELNLAGN .vertline. .vertline..vertline.:.vertline..vertline..vertline..ve rtline.::: .vertline. :.vertline..vertline.. vertline..vertline..ve rtline..vertline.:.ver tline..vertline..vertl ine..vertline..vertlin e..vertline..vertline. .vertline..vertline.: .vertline..vertline..v ertline..vertline..ver tline.:.vertline.:::.v ertline..vertline.:.ve rtline. :.vertline.:.v ertline..vertline..ver tline..vertline..vertl ine.:.vertline. MLIG-1 116 SIGVVSLFLQ HNKILSVDGSQLKSYLSLEVLD LSSNNITEIRSSCFPNGLRIRE LNLASN - LRR 5 LRR 6 LRR 7 HLIG-1 181 RIGTLELGAFDGLSRSLLTLRLSKNRITQLPVRAFKLPRLTQLDLNRNRIRLIEGLTFQG .vertline..vertline.::.vertline..vertline. .vertline..vertline..ve rtline..vertline..vert line..vertline..vertli ne..vertline..vertline ..vertline..vertline.. vertline..vertline..ve rtline..vertline..vert line..vertline..vertli ne..vertline..vertline ..vertline..vertline.. vertline..vertline..ve rtline.:.vertline..ver tline..vertline..vertl ine..vertline..vertlin e..vertline..vertline. .vertline..vertline..v ertline..vertline..ver tline..vertline..vertl ine..vertline..vertlin e..vertline..vertline. .vertline..vertline..v ertline..vertline..ver tline..vertline..vertl ine..vertline. MLIG-1 176 RISILESGAF DGLSRSLLTLRLSKNRITQLPV KAFKLPRLTQLDLNRNRIRLIE GLTGQG - LRR 8 LRR 9 HLIG-1 241 LNSLEVLKLQRNNISKLTDGAFWGLSKMHVLHLEYDSLVEVNSGSLYGLTALHQLHLSNN .vertline.:.vertline..vertline..vertline..vertline..vertline.:.ver tline..vertline..vertl ine..vertline..vertlin e..vertline..vertline. :.vertline..vertline.. vertline..vertline..ve rtline..vertline..vert line..vertline..vertli ne..vertline..vertline ..vertline..vertline.. vertline..vertline..ve rtline..vertline..vert line..vertline.:.vertl ine..vertline..vertlin e..vertline..vertline. .vertline..vertline..v ertline..vertline..ver tline..vertline..vertl ine..vertline..vertlin e..vertline..vertline. .vertline..vertline..v ertline..vertline..ver tline..vertline..vertl ine..vertline. MLIG-1 236 LDSLEVLRLQ RNNISRLTDGAFWGLSKMHVLH LEYNSLVEVNSGSLYGLTALHQ LHLSNN - LRR 10 LRR 11 LRR 12 HLIG-1 301 SIARIHRKGWSFCQKLHELVLSFNNLTRLDEESLAELSSLSVLRLSHNSISHIAEGAFKG .vertline..vertline.:.vertline..vertline.:.vertline.:.vertline..ve rtline..vertline..vert line..vertline..vertli ne..vertline..vertline ..vertline..vertline.. vertline.:.vertline..v ertline..vertline..ver tline..vertline..vertl ine..vertline..vertlin e..vertline..vertline. .vertline..vertline..v ertline..vertline..ver tline..vertline..vertl ine..vertline..vertlin e..vertline..vertline. :.vertline..vertline.. vertline..vertline..ve rtline..vertline.:.ver tline..vertline..vertl ine..vertline..vertlin e..vertline..vertline. .vertline..vertline..v ertline..vertline. MLIG-1 296 SISRIQRDGW SFCQKLHELILSFNNLTRLDEE SLAELSSLSILRLSHNAISHIA EGAFKG - LRR 13 LRR 14 HLIG-1 361 LRSLRVLDLDHNEISGTIEDTSGAFSGLEFGHSKLTLFGNKIKSVAKRAFSGLEGLEHLN .vertline.:.vertline..vertline..vertline..vertline..vertline..vert line..vertline..vertli ne..vertline..vertline ..vertline..vertline.. vertline..vertline..ve rtline..vertline..vert line..vertline..vertli ne..vertline..vertline ..vertline..vertline.: .vertline..vertline.: : .vertline..vertline. .vertline..vertline..v ertline..vertline..ver tline..vertline..vertl ine..vertline..vertlin e..vertline..vertline. .vertline..vertline..v ertline..vertline..ver tline..vertline..vertl ine..vertline..vertlin e.:.vertline..vertline ..vertline..vertline.. vertline. MLIG-1 356 LKSLRVLDLDHNEISGTIEDTSGAFTGLD-NLSKLTLFGNKIKSVAKRAFSGLESLEHLN - LRR 15 COOH-Flanking trailer HLIG-1 421 LGGNAIRSVQFDAFVKMKNLKELHISSDSFLCDCQLKWLPPWLIGRMLQAFVTATCAHPE .vertline..vertline.:.vertline..vertline..vertline..vertline..vert line..vertline..vertli ne..vertline..vertline ..vertline..vertline.: .vertline..vertline..v ertline..vertline..ver tline..vertline..vertl ine..vertline.:.vertli ne..vertline..vertline .:.vertline..vertline. .vertline..vertline..v ertline..vertline..ver tline..vertline..vertl ine..vertline..vertlin e..vertline..vertline. .vertline..vertline.:. vertline..vertline..ve rtline..vertline..vert line..vertline..vertli ne..vertline..vertline ..vertline..vertline.. vertline..vertline..ve rtline..vertline..vert line. MLIG-1 415 LGENAIRSVQFDAFAKMKNLKELYISSESFLCDCQLKWLPPWLMGRMLQAFVTATCAHPE - C2-type Ig-like domain I HLIG-1 481 SLKGQSIFSVPPESFVCDDFLKPQIITQPETTMAMVGKDIRFTCSAASSSSSPMTFAWKK .vertline..vertline..vertline..vertline..vertline..vertline..vertl ine..vertline..vertlin e..vertline. .vertline .:.vertline..vertline. .vertline..vertline..v ertline..vertline..ver tline. .vertline..vert line..vertline..vertli ne..vertline..vertline ..vertline..vertline.. vertline..vertline..ve rtline..vertline..vert line.:.vertline..vertl ine..vertline..vertlin e..vertline..vertline. .vertline..vertline..v ertline..vertline..ver tline..vertline..vertl ine..vertline..vertlin e..vertline..vertline. .vertline..vertline..v ertline..vertline..ver tline..vertline..vertl ine..vertline. MLIG-1 475 SLKGQSIFSV LPDSFVCDDFPKPQIITQPETT MAVVGKDIRFTCSAASSSSSPM TFAWKK - HLIG-1 541 DNEVLTNADMENFVHVHAQDGEVMEYTTILHLRQVTFGHEGRYQCVITNHFGSTYSHK AR .vertline..vertline..vertline..vertline..vertline.:.vertline..vert line..vertline..vertli ne..vertline..vertline ..vertline.:.vertline. .vertline.:.vertline.. vertline..vertline..ve rtline..vertline..vert line..vertline..vertli ne..vertline..vertline ..vertline..vertline.. vertline..vertline..ve rtline..vertline.:.ver tline..vertline..vertl ine..vertline..vertlin e..vertline..vertline. .vertline..vertline..v ertline..vertline.:.ve rtline..vertline..vert line..vertline..vertli ne..vertline..vertline ..vertline..vertline.. vertline..vertline..ve rtline..vertline..vert line. MLIG-1 535 DNEVLANADMENFAHVRAQDGEVMEYTTILHLRHVTFGHEGRYQCIITNHFGSTYSHKAR - C2-type Ig-like domain II HLIG-1 601 LTVNVLPSFTKTPHDITIRTTTVARLECAATGHPNPQIAWQKDGGTDFPAARARRMHVMP .vertline..vertline..vertline..vertline..vertline..vertline..vertl ine..vertline..vertlin e..vertline..vertline. :.vertline..vertline.. vertline..vertline.:.v ertline..vertline..ver tline.:.vertline.:.ver tline..vertline..vertl ine..vertline..vertlin e..vertline..vertline. .vertline..vertline..v ertline..vertline..ver tline..vertline..vertl ine..vertline..vertlin e..vertline..vertline. .vertline..vertline..v ertline..vertline..ver tline..vertline..vertl ine..vertline..vertlin e..vertline..vertline. .vertline..vertline..v ertline..vertline..ver tline..vertline..vertl ine..vertline. MLIG-1 595 LTVNVLPSFT KIPHDIAIRTGTTARLECAATG HPNPQIAWQKDGGTDFPAARER RMHVMP - HLIG-1 661 DDDVFFITDVKIDDAGVYSCTAQNSAGSISANATLTVLETPSLVVPLEDRVVSVGETV AL .vertline..vertline..vertline..vertline..vertline..vertline..vertl ine..vertline..vertlin e..vertline..vertline. .vertline..vertline..v ertline. .vertline..ve rtline..vertline..vert line..vertline..vertli ne..vertline..vertline ..vertline..vertline.. vertline..vertline..ve rtline.:.vertline..ver tline..vertline..vertl ine..vertline..vertlin e..vertline..vertline. .vertline..vertline..v ertline..vertline..ver tline..vertline.:.vert line..vertline..vertli ne..vertline..vertline ..vertline..vertline.. vertline.:.vertline..v ertline..vertline..ver tline..vertline..vertl ine.: MLIG-1 665 DDDVFFITDVKIDDMGVYSCTAQNSAGSVSANATLTVLETPSLAVPLEDRVVTVGETVAF - C2-type Ig-like domain III HLIG-1 721 QCKATGNPPPRITWFKGDRPLSLTERHHLTPDNQLLVVQNVVAEDAGRYTCEMSNTLGTE .vertline..vertline..vertline..vertline..vertline..vertline.:.vert line.:.vertline..vertl ine..vertline..vertlin e..vertline.:.vertline ..vertline.:.vertline. .vertline..vertline..v ertline..vertline..ver tline..vertline..vertl ine..vertline..vertlin e.:.vertline..vertline .:.vertline..vertline. .vertline..vertline..v ertline..vertline..ver tline..vertline..vertl ine.: :.vertline..vert line..vertline..vertli ne..vertline..vertline ..vertline..vertline.. vertline..vertline..ve rtline.:.vertline..ver tline..vertline..vertl ine. MLIG-1 715 QCKATGSPTPRITWLKGGRPLSLTERHHFTPGNQLLVVQNVMIDDAGRYTCEMSNPLGTE - HLIG-1 781 RAHSQLSVLPAAGCRKDGTTVGIFTIAVVSSIVLTSLVWVCIIYQTRKKSEEYSVTNT DE .vertline..vertline..vertline..vertline..vertline..vertline..vertl ine.:.vertline..vertli ne.::.vertline..vertli ne..vertline..vertline ..vertline..vertline.. vertline..vertline..ve rtline..vertline..vert line..vertline..vertli ne..vertline..vertline ..vertline..vertline.: .vertline..vertline..v ertline..vertline..ver tline..vertline..vertl ine..vertline..vertlin e..vertline..vertline. .vertline..vertline..v ertline..vertline..ver tline..vertline..vertl ine..vertline..vertlin e..vertline..vertline. .vertline..vertline..v ertline..vertline..ver tline..vertline..vertl ine..vertline. MLIG-1 775 RAHSQLSILP TPGCRKDGTTVGIFTIAVVCSI VLTSLVWVCIIYQTRKKSEEYS VTNTDE - HLIG-1 841 TVVPPDVPSYLSSQGTLSDRQETVVRTEGGPQANGHIESNGVCPRDASHFPEPDTHSV AC .vertline.:.vertline..vertline..vertline..vertline..vertline..vert line..vertline..vertli ne..vertline..vertline ..vertline..vertline.. vertline..vertline..ve rtline..vertline..vert line..vertline..vertli ne..vertline..vertline ..vertline..vertline.. vertline..vertline..ve rtline..vertline..vert line.:.vertline..vertl ine..vertline..vertlin e..vertline..vertline. .vertline..vertline..v ertline..vertline..ver tline..vertline. .vertline..vertline.:. vertline. .vertline..v ertline..vertline. .vertline.:.vertline.. vertline.::.vertline. MLIG-1 835 TIVPPDVPSYLSSQGTLSDRQETVVRTEGGHQANGHIESNGVCLRDPSLFPEVDIHSTTC - HLIG-1 901 RQPKLCAGSAYHKEPWKAMEKAEGTPGPHKMEHGGRVVCSDCNTEVDCYSRGQAFHPQ PV .vertline..vertline..vertline..vertline..vertline..vertline.:.vert line. .vertline. :.vertline..vertline.. vertline..vertline.: .vertline..vertline..v ertline.: .vertline.:: .vertline..vertline.: :.vertline.:.vertline. ::.vertline..vertline. .vertline..vertline..v ertline.:.vertline.:: .vertline.:.vert line..vertline..vertli ne..vertline..vertline . MLIG-1 895 RQPKLCVG--YTREPWKVTEKADRTAAPHTTAHSGSAVCSDCSTDT-------AYHPQPV - HLIG-1 961 SRDSAQPSAPNGPEPGGSDQEHSPHHQCSRTAAGSCPECQGSLYPSNHDRMLTAVKKK PM :.vertline..vertline..vertline.:.vertline..vertline.::::::.vertlin e. .vertline.:.vert line.:.vertline..vertl ine..vertline..vertlin e.::.vertline. .vertline..vertline.:. vertline..vertline. : : .vertline..vertline. .vertline..vertline..v ertline..vertline..ver tline..vertline..vertl ine..vertline.:.vertli ne.:::.vertline.:.vert line.: MLIG-1 946 PRDSGQPGTASSQELRQHDREYSPHHPYSGTADGSHTLSGGSLYPSNHDRILPSLKNKA- - HLIG-11021 ASLDGKGDSSWTLARLYHPDSTELQPASSLTSGSPE------RAEAQYLLVSNGHLPK AC .vertline..vertline. .vertline..vertline.:.vertline..vertline..ver tline..vertline..vertl ine..vertline..vertlin e..vertline.:.vertline .:::.vertline.:::.vert line.:.vertline.:::.ve rtline.:.vertline..ver tline..vertline..vertl ine..vertline. ::.vertline..vertline. .vertline.:.vertline.. vertline..vertline..ve rtline..vertline..vert line..vertline..vertli ne..vertline..vertline ..vertline..vertline. MLIG-11005 ASADGNGDSSWTLAKLHEADCIDLKPSPTLASGSPELMEDAISTEAQHLLVSNGHLPKAC - HLIG-11075 DASPESTPLTGQLPGKQRVPLLLAPKS (AA'S 1-1101 OF SEQ ID NO:2) .vertline.:.ver tline..vertline..vertl ine..vertline.:.vertli ne..vertline.:.vertlin e..vertline.::.vertlin e..vertline.:.vertline . .vertline..vertline. .vertline..vertline..v ertline..vertline.:.ve rtline. MLIG-11065 DSSPESVPLKGQITGKRRGPLLLAPRS

Example 3

Homology with Other DNA and Protein Sequences

As noted above in the section "polynucleotides of the invention", the HLIG-1 protein shows homology to several other proteins. Proteins of identified function that show the closest homology are mammalian insulin binding protein acid labile subunit (IBP-ALS) and the drosophila proteins slit and peroxidasin (see the alignments below). This homology is primarily localized to the LRR region and is largely due to the consensus leucine and asparagine residues characteristic of LRRs. As noted in the background section, above, the structure of RI predicts that these consensus residues are not involved in ligand recognition and thus the observed homology is not a strong predictor of which proteins bind to HLIG-1.

Homology of Amino Acids 134-488 of SEQ ID NO:2 with IBP-ALS: HLIG-1 134 NRSLDGSQLKAYLSLEVLDLNLNNITEVRNTYFPHGPPI--KELNLAGNRIGTLELGAFD 191 (SEQ ID NO:6) .vertline.::.vertline.:: .vertline.: ::.vertline. .vertline.:.vertline ..vertline.::::: :.vertline..vertline .: ALS 36 AEGPQCPVACTCSHDDYTDELSVFCSSKNLTHLPDDIPVSTRALWLDGNNLSSIPSAAFQ 95 - HLIG-1192 GLSRSLLTLRLSKNRITQLP VRA-FKLPRLTQLDLNRNRI RLIEGLTFQGLNSLEVLKLQ 250 :.vertline..vertline. .vertline..vertline. .vertline.:.vertline. ::: .vertline. :.vertline. : .vertline.::.vertlin e. .vertline.:.vert line.:.vertline..ver tline..vertline.:.ve rtline. :: .vertline. .vertline..vertline. : .vertline.:.vertli ne. ALS 96 NLS-SLDFLNLQGSWLRSLEPQALLGLQNLYYLHLERNRLRNLAVGLFTHTPSLASLSLS 154 - HLIG-1251 RNNISKLTDGAFWGLSKMHVLHLEYDSLVEVNSGSLYGLTALHQLHLSNNSIARIHRKG W 310 :.vertline. :::.vertline.::.vertline. .vertline. .vertline..vertlin e..vertline.:: .vertline.:.vertline .:::.vertline..vertl ine..vertline. : :: : .vertline..vertlin e.::.vertline..vertl ine.:.vertline. .vertline.::.vertlin e.::: ::: ALS155 SNLLGRLEEGLFQGLSHLWDLNLGWNSLVVLPDTVFQGLGNLHELVLAGNKLTYLQPA-- 212 - HLIG-1311 SFC--QKLHELVLSFNNLTRLDEESLAELSSLSVLRLSHNSISHIAEGAFKGLRSLRVL D 368 .vertline..vertline. :.vertline.:.vertline..vertline. .vertline. .vertline. .vertline .:.vertline. ::::: :::.vertline.::.vert line. .vertline. .vertline.::.vertlin e. .vertline.: :.vertline. .vertline..vertline. .vertline. .vertline .:::.vertline..vertl ine. .vertline..vert line. ALS213 LFCGLGELRELDLSRNALRSVKANVFVHLPRLQKLYLDRNLITAVAPGAFLGMKALRWLD 272 - HLIG-1369 LDHNEISGTIEDTSGAFSGLEFGHSKLTLFGNKIKSVAKRAFSGLEGLEHLNLGGNAIR S 428 .vertline.:.vertline..vertline. ::.vertline. :.vertline..vertline.. vertline. .vertline.:.vertline ..vertline. :.vertline. .vertline. .vertline . .vertline. .vertline. .vertline .: .vertline.:.vert line.::.vertline.: .vertline..vertline. :.vertline.:.vertlin e..vertline. .vertline. .vertline ..vertline. ALS273 LSHNRVAGLMED T---FPGL-LGLHVLRLAHN AIASLRPRTFKDLHFLEELQ LGHNRIRQ 328 - HLIG-1429 VQFDAFVKMKNLKELHISSD SFLCDCQLKWLPPWLIGRML QAFVTATCAHPESLKGQSIF 488 : :.vertline. : :.vertline.: .vertline. :::: ALS329 LGERTFEGLGQLEVLTLNDNQITEVRVGAFSGLFNVAVMNLSGNCLRSLRERVFQGLDKL 388 Homlogy of Amino Acids 268-506 of SEQ ID NO:2 with the drosophila protein slit: HLIG-1 268 MHVLHLEYDSLVEVNSGSLYGLTALHQLHLSNNSIARIHRKGWSFCQKLHELVLSFNNLT 327 (SEQ ID NO:7) .vertline.::::::::.vertline..vertline . :::::: .vertline. .vertline. .vertline..vertline ..vertline..vertlin e. SLIT 57 GIHIPGGGVGVITEARCPRVCSCTGLNVDCSHRGLTSVPRK---ISADVERLELQGNNLT 113 - HLIG-1 328 RLDEESLAELSSLSVLRLSHNSISHIAEGAFKGLRSLRVLDLDHNEISGTIEDTSGAF SG 387 : .vertline.:::: .vertline.::.vertline.::.vertline.:.vertline.::. vertline. .vertline . .vertline.: ::.vertline.::.vert line. .vertline..ve rtline. .vertline. .vertline.:::.vertl ine. .vertline.::: :: :.vertline.:.v ertline. SLIT 114 VIYETDFQRLTKLRMLQLTDNQIHTIERNSFQDLVSLERLDISNNVITTV---GRRVFKG 170 - HLIG-1 388 LEFGHSKLTLFGNKIKSVAKRAFSGLEGLEHLNLGGNAIRSVQGDAFVKMKNLKELHI SS 447 : : ::.vertline. .vertline. :.vertline.:.vertline.::::::.vertline ..vertline.:.vertli ne..vertline. :.vertline..vertlin e. .vertline.:.vert line.::.vertline.:: .vertline.:: : .vertline. : :.vertline.::.vertl ine.::.vertline.: SLIT 171 AQ-SLRSLQ LDNNQITCLDEHAFKGLVE LEILTLNNNNLTSLPHNIF GGLGRLRALRLSD 229 - HLIG-1 448 DSFLCDCQLKWLPPWL-IG RMLQAFVTATCAHPESLKG QSIFSVPPESFVCDDFLKP QII 506 ::.vertline. .vertline..vertline..vertline.:.vertline.:.vertline.. vertline.:::.vertli ne. : :.vertline.: :: : .vertline.: .vertline.: .vertline..vertline ..vertline..vertlin e.:: ::: ::.vertlin e. .vertline.::: SLIT 230 NPFACDCHL SWLSRFLRSATRLAPY--T RCQSPSQLKGQNVADLHDQ EFKCSGLTEHAPM 287 Homology of Amino Acids 188-367 of SEQ ID NO:2 with peroxidasin (POS): HLIG-1 188 GAFDGLSRSLLTLRLSKNRITQLPVRAFKLPRLTQLDLNRNRIRLIEGLTFQGLNSLEVL 247 (SEQ ID NO:8) .vertline.: : .vertline..vertline..ve rtline.: .vertline. .vertline..vertline ..vertline. .vertline.: :.vertline.: .vertline.::.vertli ne.::.vertline. POS 49 PGAGCPSRCLC FRTTVRCMHLLLEAVPAVA PQTSILDLRFNRIREIQPG AFRRLRNLNTL 108 - HLIG-1248 KLQRNNISKLTDGAFWGLS KMHVLHLEYDSLVEVNSGS LYGLTALHQLHLSNNSIAR IHR 307 .vertline.::.vertline.:.vertline.:::::.vertline..vertline..vertlin e. :.vertline.:::: .vertline.:.vertlin e. ::: :::: :: .vertline..vertline .::.vertline.:.vert line..vertline.:.ve rtline. .vertline. .vertline.: ::: POS109 LLNNNQIKRIP SGAFEDLENLKYLYLYKNE IQSIDRQAFKGLASLEQLY LHFNQIETLDP 168 - HLIG-1308 KGWSFCQKLHELVLSFNNL TRLDEESLAELSSLSVLRL SHNSISHIAEGAFKGLRSL RVL 367 ::: :.vertline..vertline.: .vertline. .vertline. .vertline.::.ve rtline.:.vertline. :::::.vertline.:.v ertline.:: .vertline..vertline ..vertline.: .vertline.:: POS169 DSFQHLPKLER LFLHNNRITHLVPGTFNHL ESMKRLRLDSNTLHCDCEI LWLADLLKTYA 228

In nucleotide comparisons, the expected moderate sequence match was observed to IGP-ALS in the region of the LRRs. However, a surprisingly high homology (93% identity for murine LIG-1) was observed to rat CHOT1 mRNA which encodes a choline transporter that does not contain LRRs. This homology is artifactual, probably occurring during CHOT1 cloning, since it lies in the extreme 5' untranslated segment of CHOT1 and matches the antisense strand of human and mouse LIG-1 within the protein coding region.

Example 4

Tissue Expression Pattern of HLIG-1

Northern blot analysis of multiple human tissues shows that HLIG-1 is highly expressed in pancreas, brain, heart and skeletal muscle as a single transcript of approximately 5.0 kb.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

__________________________________________________________________________# SEQUENCE LISTING - - - - (1) GENERAL INFORMATION: - - (iii) NUMBER OF SEQUENCES: 8 - - - - (2) INFORMATION FOR SEQ ID NO:1: - - (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4843 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - - (ii) MOLECULE TYPE: cDNA - - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: - - GCTTCGCGGC GCGTTCCAGA CAAGATGGCG CGGCCGGTCC GGGGAGGGCT CG -#GGGCCCCG 60 - - CGCCGCTCGC CTTGCCTTCT CCTTCTCTGG CTGCTTTTGC TTCGGCTGGA GC -#CGGTGACC 120 - - GCCGCGGCCG GCCCGCGGGC GCCCTGCGCG GCCGCCTGCA CTTGCGCTGG GG -#ACCCCTGC 180 - - ACTTGCGCTG GGGACTCGCT GGACTGCGGT GGGCGCGGGC TGGCTGCGTT GC -#CCGGGGAC 240 - - CTGCCCTCCT GGACGCGGAG CCTAAACCTG AGTTACAACA AACTCGCTGA GA -#TTGACCCT 300 - - GCTGGTTTTG AGGACTTGCC GAACCTACAG GAAGTGTACC TCAATAATCA TG -#AGTTGACA 360 - - GCGGTAGCAT CACTGGGCGC TGGTTCATCA CAAGTAGTCG CTCTCTTTCT GC -#AGCAGCAA 420 - - CAGAATCGCA GCCTCGACGG GAGCCAGCTG AAGGCCTACC TCTCCCTAGA AG -#TGTTAGAT 480 - - CTGAATCTGA ACAACATCAC GGAAGTGCGG AACACCTACT TTCCACACGG AC -#CGCCTATA 540 - - AAGGAGCTCA ACCTGGCAGG CAATCGGATT GGCACCCTGG AGTTGGGAGC AT -#TTGATGGT 600 - - CTGTCACGGT CGCTGCTAAC TCTTCGCCTG AGCAAAAACA GGATCACCCA GC -#TTCCTGTA 660 - - AGAGCATTCA AGCTACCCAG GCTGACACAA CTGGACCTCA ATCGGAACAG GA -#TTCGGCTG 720 - - ATAGAGGGCC TCACCTTCCA GGGGCTCAAC AGCTTGGAGG TGCTGAAGCT TC -#AGCGAAAC 780 - - AACATCAGCA AACTGACAGA TGGGGCCTTC TGGGGACTGT CCAAAATGCA TG -#TGCTGCAC 840 - - CTGGAGTACG ACAGCCTGGT AGAAGTGAAC AGCGGCTCGC TCTACGGCCT CA -#CGGCCCTG 900 - - CATCAGCTCC ACCTCAGCAA CAATTCCATC GCTCGCATTC ACCGCAAGGG CT -#GGAGCTTC 960 - - TGCCAGAAGC TGCATGAGTT GGTCCTGTCC TTCAACAACC TGACACGGCT GG -#ACGAGGAG 1020 - - AGCCTGGCCG AGCTGAGCAG CCTGAGTGTC CTGCGTCTCA GCCACAATTC CA -#TCAGCCAC 1080 - - ATTGCGGAGG GTGCCTTCAA GGGACTCAGG AGCCTGCGAG TCTTGGATCT GG -#ACCATAAC 1140 - - GAGATTTCGG GCACAATAGA GGACACGAGC GGCGCCTTCT CAGGGCTCGA AT -#TCGGCCAC 1200 - - AGCAAGCTGA CTCTGTTTGG AAACAAGATC AAGTCTGTGG CTAAGAGAGC AT -#TCTCGGGG 1260 - - CTGGAAGGCC TGGAGCACCT GAACCTTGGA GGGAATGCGA TCAGATCTGT CC -#AGTTTGAT 1320 - - GCCTTTGTGA AGATGAAGAA TCTTAAAGAG CTCCATATCA GCAGCGACAG CT -#TCCTGTGT 1380 - - GACTGCCAGC TGAAGTGGCT GCCCCCGTGG CTAATTGGCA GGATGCTGCA GG -#CCTTTGTG 1440 - - ACAGCCACCT GTGCCCACCC AGAATCACTG AAGGGTCAGA GCATTTTCTC TG -#TGCCACCA 1500 - - GAGAGTTTCG TGTGCGATGA CTTCCTGAAG CCACAGATCA TCACCCAGCC AG -#AAACCACC 1560 - - ATGGCTATGG TGGGCAAGGA CATCCGGTTT ACATGCTCAG CAGCCAGCAG CA -#GCAGCTCC 1620 - - CCCATGACCT TTGCCTGGAA GAAAGACAAT GAAGTCCTGA CCAATGCAGA CA -#TGGAGAAC 1680 - - TTTGTCCACG TCCACGCGCA GGACGGGGAA GTGATGGAGT ACACCACCAT CC -#TGCACCTC 1740 - - CGTCAGGTCA CTTTCGGGCA CGAGGGCCGC TACCAATGTG TCATCACCAA CC -#ACTTTGGC 1800 - - TCCACCTATT CACATAAGGC CAGGCTCACC GTGAATGTGT TGCCATCATT CA -#CCAAAACG 1860 - - CCCCACGACA TAACCATCCG GACCACCACC GTGGCCCGCC TCGAATGTGC TG -#CCACAGGT 1920 - - CACCCAAACC CTCAGATTGC CTGGCAGAAG GATGGAGGCA CGGATTTCCC CG -#CTGCCCGT 1980 - - GAGCGACGCA TGCATGTCAT GCCGGATGAC GACGTGTTTT TCATCACTGA TG -#TGAAAATA 2040 - - GATGACGCAG GGGTTTACAG CTGTACTGCT CAGAACTCAG CCGGTTCTAT TT -#CAGCTAAT 2100 - - GCCACCCTGA CTGTCCTAGA GACCCCATCC TTGGTGGTCC CCTTGGAAGA CC -#GTGTGGTA 2160 - - TCTGTGGGAG AAACAGTGGC CCTCCAATGC AAAGCCACGG GGAACCCTCC GC -#CCCGCATC 2220 - - ACCTGGTTCA AGGGGGACCG CCCGCTGAGC CTCACTGAGC GGCACCACCT GA -#CCCCTGAC 2280 - - AACCAGCTCC TGGTGGTTCA GAACGTGGTG GCAGAGGATG CGGGCCGATA TA -#CCTGTGAG 2340 - - ATGTCCAACA CCCTGGGCAC GGAGCGAGCT CACAGCCAGC TGAGCGTCCT GC -#CCGCAGCA 2400 - - GGCTGCAGGA AGGATGGGAC CACGGTAGGC ATCTTCACCA TTGCTGTCGT GA -#GCAGCATC 2460 - - GTCCTGACGT CACTGGTCTG GGTGTGCATC ATCTACCAGA CCAGGAAGAA GA -#GTGAAGAG 2520 - - TACAGTGTCA CCAACACAGA TGAAACCGTC GTGCCACCAG ATGTTCCAAG CT -#ACCTCTCT 2580 - - TCTCAGGGGA CCCTTTCTGA CCGACAAGAA ACCGTGGTCA GGACCGAGGG TG -#GCCCTCAG 2640 - - GCCAATGGGC ACATTGAGAG CAATGGTGTG TGTCCAAGAG ATGCAAGCCA CT -#TTCCAGAG 2700 - - CCCGACACTC ACAGCGTTGC CTGCAGGCAG CCAAAGCTCT GTGCTGGGTC TG -#CGTATCAC 2760 - - AAAGAGCCGT GGAAAGCGAT GGAGAAAGCT GAAGGGACAC CTGGGCCACA TA -#AGATGGAA 2820 - - CACGGTGGCC GGGTCGTATG CAGTGACTGC AACACCGAAG TGGACTGTTA CT -#CCAGGGGA 2880 - - CAAGCCTTCC ACCCCCAGCC TGTGTCCAGA GACAGCGCAC AGCCAAGTGC GC -#CAAATGGC 2940 - - CCGGAGCCGG GTGGGAGTGA CCAAGAGCAT TCTCCACATC ACCAGTGCAG CA -#GGACTGCC 3000 - - GCTGGGTCCT GCCCCGAGTG CCAAGGGTCG CTCTACCCCA GTAACCACGA TA -#GAATGCTG 3060 - - ACGGCTGTGA AGAAAAAGCC AATGGCATCT CTAGATGGGA AAGGGGATTC TT -#CCTGGACT 3120 - - TTAGCAAGGT TGTATCACCC GGACTCCACA GAGCTACAGC CTGCATCTTC AT -#TAACTTCA 3180 - - GGCAGTCCAG AGCGCGCGGA AGCCCAGTAC TTGCTTGTTT CCAATGGCCA CC -#TCCCCAAA 3240 - - GCATGTGACG CCAGTCCCGA GTCCACGCCA CTGACAGGAC AGCTCCCCGG GA -#AACAGAGG 3300 - - GTGCCACTGC TGTTGGCACC AAAAAGCTAG GTTTTGTCTA CCTCAGTTCT TG -#TCATACCA 3360 - - ATCTCTACGG GAAAGAGAGG TAGGAGAGGC TGCGAGGAAG CTTGGGTTCA AG -#CGTCACTC 3420 - - ATCTGTACAT AGTTGTAACT CCCATGTGGA GTATCAGTCG CTCACAGGAC TT -#GGATCTGA 3480 - - AGCACAGTAA ACGCAAGAGG GGATTTGTGT ACAAAAGGCA AAAAAAGTAT TT -#GATATCAT 3540 - - TGTACATAAG AGTTTTCAGA GATTTCATAT ATATCTTTTA CAGAGGCTAT TT -#TAATCTTT 3600 - - AGTGCATGGT TAACAGAAAA AAATTATACA ATTTTGACAA TATTATTTTT CG -#TATCAGGT 3660 - - TGCTGTTTAA TTTTGGAGGG GGTGGGGAAA TAGTTCTGGT GCCTTAACGC AT -#GGCTGGAA 3720 - - TTTATAGAGG CTACAACCAC ATTTGTTCAC AGGAGTTTTT GGTGCGGGGT GG -#GAAGGATG 3780 - - GAAGGCCTTG GATTTATATT GCACTTCATA GACCCCTAGG CTGCTGTGCG GT -#GGGACTCC 3840 - - ACATGCGCCG GAAGGAGCTT CAGGTGAGCA CTGCTCATGT GTGGATGCCC CT -#GCAACAGG 3900 - - CTTCCCTGTC TGTAGAGCCA GGGGTGCAAG TGCCATCCAC ACTTGCAGTG AA -#TGGCTTTT 3960 - - CCTTTTAGGT TTAAGTCCTG TCTGTCTGTA AGGCGTAGAA TCTGTCCGTC TG -#TAAGGCGT 4020 - - AGAATGAGGG TTGTTAATCC ATCACAAGCA AAAGGTCAGA ACAGTTAAAC AC -#TGCCTTTC 4080 - - CTCCTCCTCT TATTTTATGA TAAAAGCAAA TGTGGCCTTC TCAGTATCAT TC -#GATTGCTA 4140 - - TTTGAGACTT TTAAATTAAG GTAAAGGCTG CTGGTGTTGG TACCTGTGGA TT -#TTTCTATA 4200 - - CTGATGTTTT CGTTTTGCCA ATATAATGAG TATTACATTG GCCTTGGGGG AC -#AGAAAGGA 4260 - - GGAAGTTCTG ACTTTTCAGG GCTACCTTAT TTCTACTAAG GACCCAGAGC AG -#GCCTGTCC 4320 - - ATGCCATTCC TTCGCACAAG ATGAAACTGA GCTGGGACTG GAAAGGACAG CC -#CTTGACCT 4380 - - GGGTTTCTGG GTATAATTTG CACTTTTGAG ACTGGTAGCT AACCATCTTA TG -#AGTGCCAA 4440 - - TGTGTCATTT AGTAAAACTT AAATAGAAAC AAGGTCCTTC AAATGTTCCT TT -#GGCCAAAA 4500 - - GCTGAAGGGA GTTACTGAGA AAATAGTTAA CAATTACTGT CAGGTGTCAT CA -#CTGTTCAA 4560 - - AAGGTAAGCA CATTTAGAAT TTTGTTCTTG ACAGTTAACT GACTAATCTT AC -#TTCCACAA 4620 - - AATATGTGAA TTTGCTGCTT CTGAGAGGCA ATGTGAAAGA GGGAGTATTA CT -#TTTATGTA 4680 - - CAAAGTTATT TATTTATAGA AATTTTGGTA CAGTGTACAT TGAAAACCAT GT -#AAAATATT 4740 - - GAAGTGTCTA ACAAATGGCA TTGAAGTGTC TTTAATAAAG GTTCATTTAT AA -#AAGTCAAA 4800 - - AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAA - # 484 - #3 - - - - (2) INFORMATION FOR SEQ ID NO:2: - - (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1101 amino - #acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - - (ii) MOLECULE TYPE: protein - - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: - - Met Ala Arg Pro Val Arg Gly Gly Leu Gly Al - #a Pro Arg Arg Ser Pro 1 5 - # 10 - # 15 - - Cys Leu Leu Leu Leu Trp Leu Leu Leu Leu Ar - #g Leu Glu Pro Val Thr 20 - # 25 - # 30 - - Ala Ala Ala Gly Pro Arg Ala Pro Cys Ala Al - #a Ala Cys Thr Cys Ala 35 - # 40 - # 45 - - Gly Asp Pro Cys Thr Cys Ala Gly Asp Ser Le - #u Asp Cys Gly Gly Arg 50 - # 55 - # 60 - - Gly Leu Ala Ala Leu Pro Gly Asp Leu Pro Se - #r Trp Thr Arg Ser Leu 65 - #70 - #75 - #80 - - Asn Leu Ser Tyr Asn Lys Leu Ala Glu Ile As - #p Pro Ala Gly Phe Glu 85 - # 90 - # 95 - - Asp Leu Pro Asn Leu Gln Glu Val Tyr Leu As - #n Asn His Glu Leu Thr 100 - # 105 - # 110 - - Ala Val Ala Ser Leu Gly Ala Gly Ser Ser Gl - #n Val Val Ala Leu Phe 115 - # 120 - # 125 - - Leu Gln Gln Gln Gln Asn Arg Ser Leu Asp Gl - #y Ser Gln Leu Lys Ala 130 - # 135 - # 140 - - Tyr Leu Ser Leu Glu Val Leu Asp Leu Asn Le - #u Asn Asn Ile Thr Glu 145 1 - #50 1 - #55 1 -#60 - - Val Arg Asn Thr Tyr Phe Pro His Gly Pro Pr - #o Ile Lys Glu LeuAsn 165 - # 170 - # 175 - - Leu Ala Gly Asn Arg Ile Gly Thr Leu Glu Le - #u Gly Ala Phe Asp Gly 180 - # 185 - # 190 - - Leu Ser Arg Ser Leu Leu Thr Leu Arg Leu Se - #r Lys Asn Arg Ile Thr 195 - # 200 - # 205 - - Gln Leu Pro Val Arg Ala Phe Lys Leu Pro Ar - #g Leu Thr Gln Leu Asp 210 - # 215 - # 220 - - Leu Asn Arg Asn Arg Ile Arg Leu Ile Glu Gl - #y Leu Thr Phe Gln Gly 225 2 - #30 2 - #35 2 -#40 - - Leu Asn Ser Leu Glu Val Leu Lys Leu Gln Ar - #g Asn Asn Ile SerLys 245 - # 250 - # 255 - - Leu Thr Asp Gly Ala Phe Trp Gly Leu Ser Ly - #s Met His Val Leu His 260 - # 265 - # 270 - - Leu Glu Tyr Asp Ser Leu Val Glu Val Asn Se - #r Gly Ser Leu Tyr Gly 275 - # 280 - # 285 - - Leu Thr Ala Leu His Gln Leu His Leu Ser As - #n Asn Ser Ile Ala Arg 290 - # 295 - # 300 - - Ile His Arg Lys Gly Trp Ser Phe Cys Gln Ly - #s Leu His Glu Leu Val 305 3 - #10 3 - #15 3 -#20 - - Leu Ser Phe Asn Asn Leu Thr Arg Leu Asp Gl - #u Glu Ser Leu AlaGlu 325 - # 330 - # 335 - - Leu Ser Ser Leu Ser Val Leu Arg Leu Ser Hi - #s Asn Ser Ile Ser His 340 - # 345 - # 350 - - Ile Ala Glu Gly Ala Phe Lys Gly Leu Arg Se - #r Leu Arg Val Leu Asp 355 - # 360 - # 365 - - Leu Asp His Asn Glu Ile Ser Gly Thr Ile Gl - #u Asp Thr Ser Gly Ala 370 - # 375 - # 380 - - Phe Ser Gly Leu Glu Phe Gly His Ser Lys Le - #u Thr Leu Phe Gly Asn 385 3 - #90 3 - #95 4 -#00 - - Lys Ile Lys Ser Val Ala Lys Arg Ala Phe Se - #r Gly Leu Glu GlyLeu 405 - # 410 - # 415 - - Glu His Leu Asn Leu Gly Gly Asn Ala Ile Ar - #g Ser Val Gln Phe Asp 420 - # 425 - # 430 - - Ala Phe Val Lys Met Lys Asn Leu Lys Glu Le - #u His Ile Ser Ser Asp 435 - # 440 - # 445 - - Ser Phe Leu Cys Asp Cys Gln Leu Lys Trp Le - #u Pro Pro Trp Leu Ile 450 - # 455 - # 460 - - Gly Arg Met Leu Gln Ala Phe Val Thr Ala Th - #r Cys Ala His Pro Glu 465 4 - #70 4 - #75 4 -#80 - - Ser Leu Lys Gly Gln Ser Ile Phe Ser Val Pr - #o Pro Glu Ser PheVal 485 - # 490 - # 495 - - Cys Asp Asp Phe Leu Lys Pro Gln Ile Ile Th - #r Gln Pro Glu Thr Thr 500 - # 505 - # 510 - - Met Ala Met Val Gly Lys Asp Ile Arg Phe Th - #r Cys Ser Ala Ala Ser 515 - # 520 - # 525 - - Ser Ser Ser Ser Pro Met Thr Phe Ala Trp Ly - #s Lys Asp Asn Glu Val 530 - # 535 - # 540 - - Leu Thr Asn Ala Asp Met Glu Asn Phe Val Hi - #s Val His Ala Gln Asp 545 5 - #50 5 - #55 5 -#60 - - Gly Glu Val Met Glu Tyr Thr Thr Ile Leu Hi - #s Leu Arg Gln ValThr 565 - # 570 - # 575 - - Phe Gly His Glu Gly Arg Tyr Gln Cys Val Il - #e Thr Asn His Phe Gly 580 - # 585 - # 590 - - Ser Thr Tyr Ser His Lys Ala Arg Leu Thr Va - #l Asn Val Leu Pro Ser 595 - # 600 - # 605 - - Phe Thr Lys Thr Pro His Asp Ile Thr Ile Ar - #g Thr Thr Thr Val Ala 610 - # 615 - # 620 - - Arg Leu Glu Cys Ala Ala Thr Gly His Pro As - #n Pro Gln Ile Ala Trp 625 6 - #30 6 - #35 6 -#40 - - Gln Lys Asp Gly Gly Thr Asp Phe Pro Ala Al - #a Arg Glu Arg ArgMet 645 - # 650 - # 655 - - His Val Met Pro Asp Asp Asp Val Phe Phe Il - #e Thr Asp Val Lys Ile 660 - # 665 - # 670 - - Asp Asp Ala Gly Val Tyr Ser Cys Thr Ala Gl - #n Asn Ser Ala Gly Ser 675 - # 680 - # 685 - - Ile Ser Ala Asn Ala Thr Leu Thr Val Leu Gl - #u Thr Pro Ser Leu Val 690 - # 695 - # 700 - - Val Pro Leu Glu Asp Arg Val Val Ser Val Gl - #y Glu Thr Val Ala Leu 705 7 - #10 7 - #15 7 -#20 - - Gln Cys Lys Ala Thr Gly Asn Pro Pro Pro Ar - #g Ile Thr Trp PheLys 725 - # 730 - # 735 - - Gly Asp Arg Pro Leu Ser Leu Thr Glu Arg Hi - #s His Leu Thr Pro Asp 740 - # 745 - # 750 - - Asn Gln Leu Leu Val Val Gln Asn Val Val Al - #a Glu Asp Ala Gly Arg 755 - # 760 - # 765 - - Tyr Thr Cys Glu Met Ser Asn Thr Leu Gly Th - #r Glu Arg Ala His Ser 770 - # 775 - # 780 - - Gln Leu Ser Val Leu Pro Ala Ala Gly Cys Ar - #g Lys Asp Gly Thr Thr 785 7 - #90 7 - #95 8 -#00 - - Val Gly Ile Phe Thr Ile Ala Val Val Ser Se - #r Ile Val Leu ThrSer 805 - # 810 - # 815 - - Leu Val Trp Val Cys Ile Ile Tyr Gln Thr Ar - #g Lys Lys Ser Glu Glu 820 - # 825 - # 830 - - Tyr Ser Val Thr Asn Thr Asp Glu Thr Val Va - #l Pro Pro Asp Val Pro 835 - # 840 - # 845 - - Ser Tyr Leu Ser Ser Gln Gly Thr Leu Ser As - #p Arg Gln Glu Thr Val 850 - # 855 - # 860 - - Val Arg Thr Glu Gly Gly Pro Gln Ala Asn Gl - #y His Ile Glu Ser Asn 865 8 - #70 8 - #75 8 -#80 - - Gly Val Cys Pro Arg Asp Ala Ser His Phe Pr - #o Glu Pro Asp ThrHis 885 - # 890 - # 895 - - Ser Val Ala Cys Arg Gln Pro Lys Leu Cys Al - #a Gly Ser Ala Tyr His 900 - # 905 - # 910 - - Lys Glu Pro Trp Lys Ala Met Glu Lys Ala Gl - #u Gly Thr Pro Gly Pro 915 - # 920 - # 925 - - His Lys Met Glu His Gly Gly Arg Val Val Cy - #s Ser Asp Cys Asn Thr 930 - # 935 - # 940 - - Glu Val Asp Cys Tyr Ser Arg Gly Gln Ala Ph - #e His Pro Gln Pro Val 945 9 - #50 9 - #55 9 -#60 - - Ser Arg Asp Ser Ala Gln Pro Ser Ala Pro As - #n Gly Pro Glu ProGly 965 - # 970 - # 975 - - Gly Ser Asp Gln Glu His Ser Pro His His Gl - #n Cys Ser Arg Thr Ala 980 - # 985 - # 990 - - Ala Gly Ser Cys Pro Glu Cys Gln Gly Ser Le - #u Tyr Pro Ser Asn His 995 - # 1000 - # 1005 - - Asp Arg Met Leu Thr Ala Val Lys Lys Lys Pr - #o Met Ala Ser Leu Asp 1010 - # 1015 - # 1020 - - Gly Lys Gly Asp Ser Ser Trp Thr Leu Ala Ar - #g Leu Tyr His Pro Asp 025 1030 - # 1035 - # 1040 - - Ser Thr Glu Leu Gln Pro Ala Ser Ser Leu Th - #r Ser Gly Ser Pro Glu 1045 - # 1050 - # 1055 - - Arg Ala Glu Ala Gln Tyr Leu Leu Val Ser As - #n Gly His Leu Pro Lys 1060 - # 1065 - # 1070 - - Ala Cys Asp Ala Ser Pro Glu Ser Thr Pro Le - #u Thr Gly Gln Leu Pro 1075 - # 1080 - # 1085 - - Gly Lys Gln Arg Val Pro Leu Leu Leu Ala Pr - #o Lys Ser 1090 - # 1095 - # 1100 - - - - (2) INFORMATION FOR SEQ ID NO:3: - - (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3159 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - - (ii) MOLECULE TYPE: cDNA - - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: - - ACGCCCCACG ACATAACCAT CCGGACCACC ACCGTGGCCC GCCTCGAATG TG -#CTGCCACA 60 - - GGTCACCCAA ACCCTCAGAT TGCCTGGCAG AAGGATGGAG GCACGGATTT CC -#CCGCTGCC 120 - - CGTGAGCGAC GCATGCATGT CATGCCGGAT GACGACGTGT TTTTCATCAC TG -#ATGTGAAA 180 - - ATAGATGACG CAGGGGTTTA CAGCTGTACT GCTCAGAACT CAGCCGGTTC TA -#TTGNTACA 240 - - GCTAATGCCA CCCTGACTGT CCTAGAGACC CCATCCTTGG TGGTCCCCTT GG -#AAGACCGT 300 - - GTGGTATCTG TGGGAGAAAC AGTGGCCCTC CAATGCAAAG CCACGGGGAA CC -#CTCTGCCC 360 - - CGCATCACCT GGTTCAAGGG GGACCTCCCG CTGAAGACCT GCACTGAGCC GG -#GCACCACT 420 - - TGACCCCTGA CAACCAGCTC CTGGTGGTTC AGAACGTGGT GGGCAGAGGA TG -#CGGGCCGA 480 - - TATACCTGTG AGATGTCCAA CACCCTGGGC ACGGAGCGAG CTCACAGTCC AG -#CTGAGCGT 540 - - CCCTGCCCGC AGACAGGCTG CAGGTAAGGA TTGGAACCAC GGTTGGCATC TT -#CCACCATT 600 - - GACTGTCGTG AGCCAGCATC GTCCTGACGT CACTGGATCT TGGGTTTGGA TT -#CATCTATC 660 - - AGAACCAGGA AGAAGAGTGA AGAGTTACAG TTTTCCCCAC AACCAGGTTG AA -#AACCGTTG 720 - - GTGGCACCAG ATGTTCCAAG CTACCTCTCT TCTCAGGGGA CCCTTTCTGA CC -#GACAAGAA 780 - - ACCGTGGTCC AGGACCGAGG GTTCGGCCCT GAGGGCAATG GGCACATTGA GA -#GCAATGGT 840 - - GTGTGTCCAA GAGATGCAAG CCACTTTCCA GAGCCCGACA CTCACAGCGT TG -#CCTGCAGG 900 - - CAGCCAAAGC TCTGTGCTGG GTCTGGGTAT CACAAAGAGC CGTGGAAAGC GA -#TGGAGAAA 960 - - GCTGGAAGGG ACACCTGGGC CACATGAAGA TGGGAACACG GTGGACCGGG TC -#GTATGCAG 1020 - - TGACTGCAAC ACCGAAGTGG CAGAGACTGT TTACTCCAGG GGAACAAGCC TT -#CCACCCCC 1080 - - AGCCTGTGTC CAGAGGACAG TGCACAGCCA AGTGGGCCAA AATGGTCCCG GA -#GCCGGGTG 1140 - - GGGAAGTGAC CAAGAGGCAT TCTTCCACAT CACCATTGCA GGAGGATTGC CG -#TTGGGTCC 1200 - - TGCCCCGAGT GGCCCAGGGT TGTTTTTAAC CCCATTAACC ACGTTAGAAT GT -#TTTTTGAC 1260 - - GGTTTTTGAA GGAAAAGCCA TTGGCATCTC TAGATGGGAA AGGGGATTCT TC -#CTGGACTT 1320 - - TAGCAAGGTT GTATCACCCG GACTCCACAG AGCTACAGCC TGCATCTTCA TT -#AACTTCAG 1380 - - GCAGTCCAGA GCGCGCGGAA GCCCAGTACT TGCTTGTTTC CAATGGCCAC CT -#CCCCAAAG 1440 - - CATGTGACGC CAGTCCCGAG TCCACGCCAC TGACAGGACA GCTCCCCGGG AA -#ACAGAGGG 1500 - - TGCCACTGCT GTTGGCACCA AAAAGCTAGG TTTTGTCTAC CTCAGTTCTT GG -#TCATACCA 1560 - - ATCTCTACGG GAAAGAGAGG TAGGAGAGGC TGCGAGGAAG CTTGGGTTCA AG -#CGTCACTC 1620 - - ATCTGTACAT AGTTGTAACT CCCATGTGGA GTATCCAGTC GTTCACAGGA CT -#TGGGATCT 1680 - - GAAGCACAGT AAACGCAAGA GGGGGATTTG TGTACCAAAA GGCAAAAAAA AG -#TATTTGAT 1740 - - ATCCATTGTA CCATAAGGGT TTTCAGGGGT TTCATATATA TCCTTTTAAC AG -#AGGTTATT 1800 - - TTAATCTTTA GTGCATGGTT AACCGGAAAA AATTTTTCCA TTTTGGCCAT TT -#TATTTTTC 1860 - - CGTATCCAGG TTGCTGTTTA ATTTTGGAGG GGGTTGGGGA AATAGTTCTG GT -#GCCTTAAC 1920 - - GCATGGCTGG GAATTTATAG AGGCTACAAC CACATTTGTT CACAGGAAGT TT -#TTGGTGCG 1980 - - GGGTGGGAAG GATGGAAGGC CTTGGAATTT ATATTGCACT TCATAGACCC CT -#AGGCTGCT 2040 - - GTGCGGTGGG ACTCCACATG CGCCCGGAAG GAGCTTTCAG GTGAGCACTG CT -#CATGTGTG 2100 - - GATGCCCCTG CAACAGGCTT CCCTGTCTGT AGAGCCAGGG GTGCAAGTGC CC -#ATCCACAC 2160 - - TTGCAGTGAA TGGCTTTTCC TTTTAGTTTT AAGTCCTGTC TGTTTTTAAG GC -#GTAGGATT 2220 - - TGTCCTTCTG TAAGGCGTGG AATGAGGGTT GTTAATCCAT CACAAGCAAA AG -#GTCCGAAC 2280 - - CGTTAAACAC TGCCTTTCCT CCTCCTTATT TTGGTTCCCT TATTTTATGT TA -#AAAGCAAA 2340 - - TGTGGCCTTC TCAGTATCAT TCGATTGCTA TTTGAGACTT TTAAATTAAG GT -#AAAGGCTG 2400 - - CTGGTGTTGG TACCTGTGGA TTTTTCTATA CTGATGTTTT CGTTTTGCCA AT -#ATAATGAG 2460 - - TATTACATTG GCCTTGGGGG ACAGAAAGGA GGAAGTTCTG ACTTTTCAGG GC -#TACCTTAT 2520 - - TTCTACTAAG GACCCAGAGC AGGCCTGTCC ATGCCATTCC TTCGCACAGA TG -#AAACTGAG 2580 - - CTGGGACTGG AAAGGACAGC CCTTGACCTG GGTTCTGGGT ATAATTTGCA CT -#TTTGAGAC 2640 - - TGGTAGCTAA CCATCTTATG AGTGCCAATG TGTCATTTAG TAAAACTTAA AT -#AGAAACAA 2700 - - GGTCCTTCAA ATGTTCCTTT GGCCAAAAGC TGAAGGGAGT TACTGAGAAA AT -#AGTTAACA 2760 - - ATTACTGTCA GGTGTCATCA CTGTTCAAAA GGTAAGCACA TTTAGAATTT TG -#TTCTTGAC 2820 - - AGTTAACTGA CTAATCTTAC TTCCACAAAA TATGTGAATT TGCTGCTTCT GA -#GAGGCAAT 2880 - - GTGAAAGAGG GAGTATTACT TTTATGTACA AAGTTATTTA TTTATAGAAA TT -#TTGGTACA 2940 - - GTGTACATTG AAAACCATGT AAAATATTGA AGTGTCTAAC AAATGGCATT GA -#AGTGTCTT 3000 - - TAATAAAGGT TCATTTATAA ATGTCAAAAT AANNNNAAGT TATTTATTTA TA -#GAAATTTT 3060 - - GGTACAGTGT ACATTGAAAA CCATGTAAAA TATTGAAGTG TNCTAACAAA TG -#GCATTGAA 3120 - - GTGTNCTTTA ATAAAGGTTC ATTTATAAAT GTCNNAAAA - # - # 3159 - - - - (2) INFORMATION FOR SEQ ID NO:4: - - (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 140 amino - #acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - - (ii) MOLECULE TYPE: protein - - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: - - Thr Pro His Asp Ile Thr Ile Arg Thr Thr Th - #r Val Ala Arg Leu Glu 1 5 - # 10 - # 15 - - Cys Ala Ala Thr Gly His Pro Asn Pro Gln Il - #e Ala Trp Gln Lys Asp 20 - # 25 - # 30 - - Gly Gly Thr Asp Phe Pro Ala Ala Arg Glu Ar - #g Arg Met His Val Met 35 - # 40 - # 45 - - Pro Asp Asp Asp Val Phe Phe Ile Thr Asp Va - #l Lys Ile Asp Asp Ala 50 - # 55 - # 60 - - Gly Val Tyr Ser Cys Thr Ala Gln Asn Ser Al - #a Gly Ser Ile Xaa Thr 65 - #70 - #75 - #80 - - Ala Asn Ala Thr Leu Thr Val Leu Glu Thr Pr - #o Ser Leu Val Val Pro 85 - # 90 - # 95 - - Leu Glu Asp Arg Val Val Ser Val Gly Glu Th - #r Val Ala Leu Gln Cys 100 - # 105 - # 110 - - Lys Ala Thr Gly Asn Pro Leu Pro Arg Ile Th - #r Trp Phe Lys Gly Asp 115 - # 120 - # 125 - - Leu Pro Leu Lys Thr Cys Thr Glu Pro Gly Th - #r Thr 130 - # 135 - # 140 - - - - (2) INFORMATION FOR SEQ ID NO:5: - - (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1091 amino - #acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - - (ii) MOLECULE TYPE: protein - - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: - - Met Ala Arg Pro Gly Pro Gly Val Leu Gly Al - #a Pro Arg Leu Ala Pro 1 5 - # 10 - # 15 - - Arg Leu Leu Leu Trp Leu Leu Leu Leu Leu Le - #u Gln Trp Pro Glu Ser 20 - # 25 - # 30 - - Ala Gly Ala Gln Ala Arg Pro Arg Ala Pro Cy - #s Ala Ala Ala Cys Thr 35 - # 40 - # 45 - - Cys Ala Gly Asn Ser Leu Asp Cys Ser Gly Ar - #g Gly Leu Ala Thr Leu 50 - # 55 - # 60 - - Pro Arg Asp Leu Pro Ser Trp Thr Arg Ser Le - #u Asn Leu Ser Tyr Asn 65 - #70 - #75 - #80 - - Arg Leu Ser Glu Ile Asp Ser Ala Ala Phe Gl - #u Asp Leu Thr Asn Leu 85 - # 90 - # 95 - - Gln Glu Val Tyr Leu Asn Ser Asn Glu Leu Th - #r Ala Ile Pro Ser Leu 100 - # 105 - # 110 - - Gly Thr Ala Ser Ile Gly Val Val Ser Leu Ph - #e Leu Gln His Asn Lys 115 - # 120 - # 125 - - Ile Leu Ser Val Asp Gly Ser Gln Leu Lys Se - #r Tyr Leu Ser Leu Glu 130 - # 135 - # 140 - - Val Leu Asp Leu Ser Ser Asn Asn Ile Thr Gl - #u Ile Arg Ser Ser Cys 145 1 - #50 1 - #55 1 -#60 - - Phe Pro Asn Gly Leu Arg Ile Arg Glu Leu As - #n Leu Ala Ser AsnArg 165 - # 170 - # 175 - - Ile Ser Ile Leu Glu Ser Gly Ala Phe Asp Gl - #y Leu Ser Arg Ser Leu 180 - # 185 - # 190 - - Leu Thr Leu Arg Leu Ser Lys Asn Arg Ile Th - #r Gln Leu Pro Val Lys 195 - # 200 - # 205 - - Ala Phe Lys Leu Pro Arg Leu Thr Gln Leu As - #p Leu Asn Arg Asn Arg 210 - # 215 - # 220 - - Ile Arg Leu Ile Glu Gly Leu Thr Phe Gln Gl - #y Leu Asp Ser Leu Glu 225 2 - #30 2 - #35 2 -#40 - - Val Leu Arg Leu Gln Arg Asn Asn Ile Ser Ar - #g Leu Thr Asp GlyAla 245 - # 250 - # 255 - - Phe Trp Gly Leu Ser Lys Met His Val Leu Hi - #s Leu Glu Tyr Asn Ser 260 - # 265 - # 270 - - Leu Val Glu Val Asn Ser Gly Ser Leu Tyr Gl - #y Leu Thr Ala Leu His 275 - # 280 - # 285 - - Gln Leu His Leu Ser Asn Asn Ser Ile Ser Ar - #g Ile Gln Arg Asp Gly 290 - # 295 - # 300 - - Trp Ser Phe Cys Gln Lys Leu His Glu Leu Il - #e Leu Ser Phe Asn Asn 305 3 - #10 3 - #15 3 -#20 - - Leu Thr Arg Leu Asp Glu Glu Ser Leu Ala Gl - #u Leu Ser Ser LeuSer 325 - # 330 - # 335 - - Ile Leu Arg Leu Ser His Asn Ala Ile Ser Hi - #s Ile Ala Glu Gly Ala 340 - # 345 - # 350 - - Phe Lys Gly Leu Lys Ser Leu Arg Val Leu As - #p Leu Asp His Asn Glu 355 - # 360 - # 365 - - Ile Ser Gly Thr Ile Glu Asp Thr Ser Gly Al - #a Phe Thr Gly Leu Asp 370 - # 375 - # 380 - - Asn Leu Ser Lys Leu Thr Leu Phe Gly Asn Ly - #s Ile Lys Ser Val Ala 385 3 - #90 3 - #95 4 -#00 - - Lys Arg Ala Phe Ser Gly Leu Glu Ser Leu Gl - #u His Leu Asn LeuGly 405 - # 410 - # 415 - - Glu Asn Ala Ile Arg Ser Val Gln Phe Asp Al - #a Phe Ala Lys Met Lys 420 - # 425 - # 430 - - Asn Leu Lys Glu Leu Tyr Ile Ser Ser Glu Se - #r Phe Leu Cys Asp Cys 435 - # 440 - # 445 - - Gln Leu Lys Trp Leu Pro Pro Trp Leu Met Gl - #y Arg Met Leu Gln Ala 450 - # 455 - # 460 - - Phe Val Thr Ala Thr Cys Ala His Pro Glu Se - #r Leu Lys Gly Gln Ser 465 4 - #70 4 - #75 4 -#80 - - Ile Phe Ser Val Leu Pro Asp Ser Phe Val Cy - #s Asp Asp Phe ProLys 485 - # 490 - # 495 - - Pro Gln Ile Ile Thr Gln Pro Glu Thr Thr Me - #t Ala Val Val Gly Lys 500 - # 505 - # 510 - - Asp Ile Arg Phe Thr Cys Ser Ala Ala Ser Se - #r Ser Ser Ser Pro Met 515 - # 520 - # 525 - - Thr Phe Ala Trp Lys Lys Asp Asn Glu Val Le - #u Ala Asn Ala Asp Met 530 - # 535 - # 540 - - Glu Asn Phe Ala His Val Arg Ala Gln Asp Gl - #y Glu Val Met Glu Tyr 545 5 - #50 5 - #55 5 -#60 - - Thr Thr Ile Leu His Leu Arg His Val Thr Ph - #e Gly His Glu GlyArg 565 - # 570 - # 575 - - Tyr Gln Cys Ile Ile Thr Asn His Phe Gly Se - #r Thr Tyr Ser His Lys 580 - # 585 - # 590 - - Ala Arg Leu Thr Val Asn Val Leu Pro Ser Ph - #e Thr Lys Ile Pro His 595 - # 600 - # 605 - - Asp Ile Ala Ile Arg Thr Gly Thr Thr Ala Ar - #g Leu Glu Cys Ala Ala 610 - # 615 - # 620 - - Thr Gly His Pro Asn Pro Gln Ile Ala Trp Gl - #n Lys Asp Gly Gly Thr 625 6 - #30 6 - #35 6 -#40 - - Asp Phe Pro Ala Ala Arg Glu Arg Arg Met Hi - #s Val Met Pro AspAsp 645 - # 650 - # 655 - - Asp Val Phe Phe Ile Thr Asp Val Lys Ile As - #p Asp Met Gly Val Tyr 660 - # 665 - # 670 - - Ser Cys Thr Ala Gln Asn Ser Ala Gly Ser Va - #l Ser Ala Asn Ala Thr 675 - # 680 - # 685 - - Leu Thr Val Leu Glu Thr Pro Ser Leu Ala Va - #l Pro Leu Glu Asp Arg 690 - # 695 - # 700 - - Val Val Thr Val Gly Glu Thr Val Ala Phe Gl - #n Cys Lys Ala Thr Gly 705 7 - #10 7 - #15 7 -#20 - - Ser Pro Thr Pro Arg Ile Thr Trp Leu Lys Gl - #y Gly Arg Pro LeuSer 725 - # 730 - # 735 - - Leu Thr Glu Arg His His Phe Thr Pro Gly As - #n Gln Leu Leu Val Val 740 - # 745 - # 750 - - Gln Asn Val Met Ile Asp Asp Ala Gly Arg Ty - #r Thr Cys Glu Met Ser 755 - # 760 - # 765 - - Asn Pro Leu Gly Thr Glu Arg Ala His Ser Gl - #n Leu Ser Ile Leu Pro 770 - # 775 - # 780 - - Thr Pro Gly Cys Arg Lys Asp Gly Thr Thr Va - #l Gly Ile Phe Thr Ile 785 7 - #90 7 - #95 8 -#00 - - Ala Val Val Cys Ser Ile Val Leu Thr Ser Le - #u Val Trp Val CysIle 805 - # 810 - # 815 - - Ile Tyr Gln Thr Arg Lys Lys Ser Glu Glu Ty - #r Ser Val Thr Asn Thr 820 - # 825 - # 830 - - Asp Glu Thr Ile Val Pro Pro Asp Val Pro Se - #r Tyr Leu Ser Ser Gln 835 - # 840 - # 845 - - Gly Thr Leu Ser Asp Arg Gln Glu Thr Val Va - #l Arg Thr Glu Gly Gly 850 - # 855 - # 860 - - His Gln Ala Asn Gly His Ile Glu Ser Asn Gl - #y Val Cys Leu Arg Asp 865 8 - #70 8 - #75 8 -#80 - - Pro Ser Leu Phe Pro Glu Val Asp Ile His Se - #r Thr Thr Cys ArgGln 885 - # 890 - # 895 - - Pro Lys Leu Cys Val Gly Tyr Thr Arg Glu Pr - #o Trp Lys Val Thr Glu 900 - # 905 - # 910 - - Lys Ala Asp Arg Thr Ala Ala Pro His Thr Th - #r Ala His Ser Gly Ser 915 - # 920 - # 925 - - Ala Val Cys Ser Asp Cys Ser Thr Asp Thr Al - #a Tyr His Pro Gln Pro 930 - # 935 - # 940 - - Val Pro Arg Asp Ser Gly Gln Pro Gly Thr Al - #a Ser Ser Gln Glu Leu 945 9 - #50 9 - #55 9 -#60 - - Arg Gln His Asp Arg Glu Tyr Ser Pro His Hi - #s Pro Tyr Ser GlyThr 965 - # 970 - # 975 - - Ala Asp Gly Ser His Thr Leu Ser Gly Gly Se - #r Leu Tyr Pro Ser Asn 980 - # 985 - # 990 - - His Asp Arg Ile Leu Pro Ser Leu Lys Asn Ly - #s Ala Ala Ser Ala Asp 995 - # 1000 - # 1005 - - Gly Asn Gly Asp Ser Ser Trp Thr Leu Ala Ly - #s Leu His Glu Ala Asp 1010 - # 1015 - # 1020 - - Cys Ile Asp Leu Lys Pro Ser Pro Thr Leu Al - #a Ser Gly Ser Pro Glu 025 1030 - # 1035 - # 1040 - - Leu Met Glu Asp Ala Ile Ser Thr Glu Ala Gl - #n His Leu Leu Val Ser 1045 - # 1050 - # 1055 - - Asn Gly His Leu Pro Lys Ala Cys Asp Ser Se - #r Pro Glu Ser Val Pro 1060 - # 1065 - # 1070 - - Leu Lys Gly Gln Ile Thr Gly Lys Arg Arg Gl - #y Pro Leu Leu Leu Ala 1075 - # 1080 - # 1085 - - Pro Arg Ser 1090 - - - - (2) INFORMATION FOR SEQ ID NO:6: - - (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 353 amino - #acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - - (ii) MOLECULE TYPE: protein - - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: - - Ala Glu Gly Pro Gln Cys Pro Val Ala Cys Th - #r Cys Ser His Asp Asp 1 5 - # 10 - # 15 - - Tyr Thr Asp Glu Leu Ser Val Phe Cys Ser Se - #r Lys Asn Leu Thr His 20 - # 25 - # 30 - - Leu Pro Asp Asp Ile Pro Val Ser Thr Arg Al - #a Leu Trp Leu Asp Gly 35 - # 40 - # 45 - - Asn Asn Leu Ser Ser Ile Pro Ser Ala Ala Ph - #e Gln Asn Leu Ser Ser 50 - # 55 - # 60 - - Leu Asp Phe Leu Asn Leu Gln Gly Ser Trp Le - #u Arg Ser Leu Glu Pro 65 - #70 - #75 - #80 - - Gln Ala Leu Leu Gly Leu Gln Asn Leu Tyr Ty - #r Leu His Leu Glu Arg 85 - # 90 - # 95 - - Asn Arg Leu Arg Asn Leu Ala Val Gly Leu Ph - #e Thr His Thr Pro Ser 100 - # 105 - # 110 - - Leu Ala Ser Leu Ser Leu Ser Ser Asn Leu Le - #u Gly Arg Leu Glu Glu 115 - # 120 - # 125 - - Gly Leu Phe Gln Gly Leu Ser His Leu Trp As - #p Leu Asn Leu Gly Trp 130 - # 135 - # 140 - - Asn Ser Leu Val Val Leu Pro Asp Thr Val Ph - #e Gln Gly Leu Gly Asn 145 1 - #50 1 - #55 1 -#60 - - Leu His Glu Leu Val Leu Ala Gly Asn Lys Le - #u Thr Tyr Leu GlnPro 165 - # 170 - # 175 - - Ala Leu Phe Cys Gly Leu Gly Glu Leu Arg Gl - #u Leu Asp Leu Ser Arg 180 - # 185 - # 190 - - Asn Ala Leu Arg Ser Val Lys Ala Asn Val Ph - #e Val His Leu Pro Arg 195 - # 200 - # 205 - - Leu Gln Lys Leu Tyr Leu Asp Arg Asn Leu Il - #e Thr Ala Val Ala Pro 210 - # 215 - # 220 - - Gly Ala Phe Leu Gly Met Lys Ala Leu Arg Tr - #p Leu Asp Leu Ser His 225 2 - #30 2 - #35 2 -#40 - - Asn Arg Val Ala Gly Leu Met Glu Asp Thr Ph - #e Pro Gly Leu LeuGly 245 - # 250 - # 255 - - Leu His Val Leu Arg Leu Ala His Asn Ala Il - #e Ala Ser Leu Arg Pro 260 - # 265 - # 270 - - Arg Thr Phe Lys Asp Leu His Phe Leu Glu Gl - #u Leu Gln Leu Gly His 275 - # 280 - # 285 - - Asn Arg Ile Arg Gln Leu Gly Glu Arg Thr Ph - #e Glu Gly Leu Gly Gln 290 - # 295 - # 300 - - Leu Glu Val Leu Thr Leu Asn Asp Asn Gln Il - #e Thr Glu Val Arg Val 305 3 - #10 3 - #15 3 -#20 - - Gly Ala Phe Ser Gly Leu Phe Asn Val Ala Va - #l Met Asn Leu SerGly 325 - # 330 - # 335 - - Asn Cys Leu Arg Ser Leu Pro Glu Arg Val Ph - #e Gln Gly Leu Asp Lys 340 - # 345 - # 350 - - Leu - - - - (2) INFORMATION FOR SEQ ID NO:7: - - (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 231 amino - #acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - - (ii) MOLECULE TYPE: protein - - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: - - Gly Ile His Ile Pro Gly Gly Gly Val Gly Va - #l Ile Thr Glu Ala Arg 1 5 - # 10 - # 15 - - Cys Pro Arg Val Cys Ser Cys Thr Gly Leu As - #n Val Asp Cys Ser His 20 - # 25 - # 30 - - Arg Gly Leu Thr Ser Val Pro Arg Lys Ile Se - #r Ala Asp Val Glu Arg 35 - # 40 - # 45 - - Leu Glu Leu Gln Gly Asn Asn Leu Thr Val Il - #e Tyr Glu Thr Asp Phe 50 - # 55 - # 60 - - Gln Arg Leu Thr Lys Leu Arg Met Leu Gln Le - #u Thr Asp Asn Gln Ile 65 - #70 - #75 - #80 - - His Thr Ile Glu Arg Asn Ser Phe Gln Asp Le - #u Val Ser Leu Glu Arg 85 - # 90 - # 95 - - Leu Asp Ile Ser Asn Asn Val Ile Thr Thr Va - #l Gly Arg Arg Val Phe 100 - # 105 - # 110 - - Lys Gly Ala Gln Ser Leu Arg Ser Leu Gln Le - #u Asp Asn Asn Gln Ile 115 - # 120 - # 125 - - Thr Cys Leu Asp Glu His Ala Phe Lys Gly Le - #u Val Glu Leu Glu Ile 130 - # 135 - # 140 - - Leu Thr Leu Asn Asn Asn Asn Leu Thr Ser Le - #u Pro His Asn Ile Phe 145 1 - #50 1 - #55 1 -#60 - - Gly Gly Leu Gly Arg Leu Arg Ala Leu Arg Le - #u Ser Asp Asn ProPhe 165 - # 170 - # 175 - - Ala Cys Asp Cys His Leu Ser Trp Leu Ser Ar - #g Phe Leu Arg Ser Ala 180 - # 185 - # 190 - - Thr Arg Leu Ala Pro Tyr Thr Arg Cys Gln Se - #r Pro Ser Gln Leu Lys 195 - # 200 - # 205 - - Gly Gln Asn Val Ala Asp Leu His Asp Gln Gl - #u Phe Lys Cys Ser Gly 210 - # 215 - # 220 - - Leu Thr Glu His Ala Pro Met 225 2 - #30 - - - - (2) INFORMATION FOR SEQ ID NO:8: - - (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 180 amino - #acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - - (ii) MOLECULE TYPE: protein - - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: - - Pro Gly Ala Gly Cys Pro Ser Arg Cys Leu Cy - #s Phe Arg Thr Thr Val 1 5 - # 10 - # 15 - - Arg Cys Met His Leu Leu Leu Glu Ala Val Pr - #o Ala Val Ala Pro Gln 20 - # 25 - # 30 - - Thr Ser Ile Leu Asp Leu Arg Phe Asn Arg Il - #e Arg Glu Ile Gln Pro 35 - # 40 - # 45 - - Gly Ala Phe Arg Arg Leu Arg Asn Leu Asn Th - #r Leu Leu Leu Asn Asn 50 - # 55 - # 60 - - Asn Gln Ile Lys Arg Ile Pro Ser Gly Ala Ph - #e Glu Asp Leu Glu Asn 65 - #70 - #75 - #80 - - Leu Lys Tyr Leu Tyr Leu Tyr Lys Asn Glu Il - #e Gln Ser Ile Asp Arg 85 - # 90 - # 95 - - Gln Ala Phe Lys Gly Leu Ala Ser Leu Glu Gl - #n Leu Tyr Leu His Phe 100 - # 105 - # 110 - - Asn Gln Ile Glu Thr Leu Asp Pro Asp Ser Ph - #e Gln His Leu Pro Lys 115 - # 120 - # 125 - - Leu Glu Arg Leu Phe Leu His Asn Asn Arg Il - #e Thr His Leu Val Pro 130 - # 135 - # 140 - - Gly Thr Phe Asn His Leu Glu Ser Met Lys Ar - #g Leu Arg Leu Asp Ser 145 1 - #50 1 - #55 1 -#60 - - Asn Thr Leu His Cys Asp Cys Glu Ile Leu Tr - #p Leu Ala Asp LeuLeu 165 - # 170 - # 175 - - Lys Thr Tyr Ala 180__________________________________________________________________________

Claims

1. An isolated polynucleotide comprising a nucleotide sequence containing up to a total of 5 point mutations per 100 nucleotides of a polynucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO:2, said point mutations being selected from the group consisting of single nucleotide deletions, single nucleotide additions, and single nucleotide substitutions.

2. The isolated polynucleotide of claim 1 wherein said polynucleotide comprises the nucleotide sequence set forth in SEQ ID NO:1 encoding the polypeptide having the amino acid sequence set forth in SEQ ID NO:2.

3. The isolated polynucleotide of claim 1 wherein said polynucleotide comprises a nucleotide sequence containing up to a total of 5 point mutations per 100 nucleotides of the nucleotide sequence set forth in SEQ ID NO:1, said point mutations being selected from the group consisting of single nucleotide deletions, single nucleotide additions, and single nucleotide substitutions.

4. The isolated polynucleotide of claim 3 wherein said nucleotide sequence comprises the nucleotide sequence set forth in SEQ ID NO: 1.

5. The isolated polynucleotide of claim 1 wherein the isolated polynucleotide is DNA or RNA.

6. An expression vector comprising an isolated DNA or RNA molecule encoding a polypeptide comprising an amino acid sequence containing up to a total of 5 point mutations per 100 amino acids of the amino acid sequence set forth in SEQ ID NO:2, said point mutations being selected from the group consisting of single amino acid deletions, single amino acid additions, and single amino acid substitutions.

7. An isolated host cell transformed with the expression vector of claim 6.

8. A process for producing a polypeptide having the amino acid sequence set forth in SEQ ID NO:2 comprising culturing the host cell of claim 7 under conditions sufficient for the production of said polypeptide and recovering said polypeptide from the culture.

9. A process for producing a recombinant host cell which produces a polypeptide having the amino acid sequence set forth in SEQ ID NO:2 comprising transforming or transfecting a host cell with the expression vector of claim 6 such that the host cell, under appropriate culture conditions, produces said polypeptide.

10. A recombinant host cell produced by the method of claim 9.

11. An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide having the amino acid sequence set forth in SEQ ID NO:2.

12. The isolated polynucleotide of claim 11 wherein said polynucleotide is RNA corresponding to the entire length of the polynucleotide set forth in SEQ ID NO:1.

13. The isolated polynucleotide of claim 11 wherein said polynucleotide is RNA corresponding to the entire coding region of the polynucleotide set forth in SEQ ID NO:1.

14. An isolated polynucleotide wherein said polynucleotide is fully complementary to the nucleotide sequence that encodes the polypeptide set forth in SEQ ID NO:2.

15. The isolated polynucleotide of claim 14 wherein said polynucleotide is fully complementary to the polynucleotide sequence set forth in SEQ ID NO:1.

16. An isolated polynucleotide encoding HLIG-1 polypeptide as shown in SEQ ID NO:2 except that 1-10 encoded amino acid residues are substituted, deleted, added, or any combination thereof.